Acebutolol (Monograph)

Brand name: Sectral
Drug class: beta-Adrenergic Blocking Agents

Medically reviewed by Drugs.com on Apr 10, 2024. Written by ASHP.

Introduction

A short-acting β₁-selective adrenergic blocking agent (β-blocker).¹ ² ¹⁷ ¹⁸ ¹¹³

Uses for Acebutolol

Hypertension

Management of hypertension (alone or in combination with other classes of antihypertensive agents).¹ ²⁸⁰ ¹²⁰⁰

β-Blockers generally not preferred for first-line therapy of hypertension according to current evidence-based hypertension guidelines, but may be considered in patients who have a compelling indication (e.g., prior MI, ischemic heart disease, heart failure) for their use or as add-on therapy in those who do not respond adequately to the preferred drug classes (ACE inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, or thiazide diuretics).³⁶¹ ⁵⁰¹ ⁵⁰² ⁵⁰³ ⁵⁰⁴ ⁵¹⁵ ⁵²³ ⁵²⁴ ⁵²⁷ ⁸⁰⁰ ¹²⁰⁰ A 2017 ACC/AHA multidisciplinary hypertension guideline states that β-blockers used for ischemic heart disease that are also effective in lowering BP include bisoprolol, carvedilol, metoprolol succinate, metoprolol tartrate, nadolol, propranolol, and timolol.¹²⁰⁰

Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).⁵⁰¹ ⁵⁰² ⁵⁰³ ⁵⁰⁴ ⁵¹⁵ ¹²⁰⁰ ¹²⁰¹

The 2017 ACC/AHA hypertension guideline classifies BP in adults into 4 categories: normal, elevated, stage 1 hypertension, and stage 2 hypertension.¹²⁰⁰ (See Table 1.)

Source: Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-115.

Individuals with SBP and DBP in 2 different categories (e.g., elevated SBP and normal DBP) should be designated as being in the higher BP category (i.e., elevated BP).

Table 1. ACC/AHA BP Classification in Adults1200
Category	SBP (mm Hg)		DBP (mm Hg)
Normal	<120	and	<80
Elevated	120–129	and	<80
Hypertension, Stage 1	130–139	or	80–89
Hypertension, Stage 2	≥140	or	≥90

The goal of hypertension management and prevention is to achieve and maintain optimal control of BP.¹²⁰⁰ However, the BP thresholds used to define hypertension, the optimum BP threshold at which to initiate antihypertensive drug therapy, and the ideal target BP values remain controversial.⁵⁰¹ ⁵⁰³ ⁵⁰⁴ ⁵⁰⁵ ⁵⁰⁶ ⁵⁰⁷ ⁵⁰⁸ ⁵¹⁵ ⁵²³ ⁵²⁶ ⁵³⁰ ¹²⁰⁰ ¹²⁰¹ ¹²⁰⁷ ¹²⁰⁹ ¹²²² ¹²²³ ¹²²⁹

The 2017 ACC/AHA hypertension guideline generally recommends a target BP goal (i.e., BP to achieve with drug therapy and/or nonpharmacologic intervention) of <130/80 mm Hg in all adults regardless of comorbidities or level of atherosclerotic cardiovascular disease (ASCVD) risk.¹²⁰⁰ In addition, an SBP goal of <130 mm Hg generally is recommended for noninstitutionalized ambulatory patients ≥65 years of age with an average SBP of ≥130 mm Hg.¹²⁰⁰ These BP goals are based upon clinical studies demonstrating continuing reduction of cardiovascular risk at progressively lower levels of SBP.¹²⁰⁰ ¹²⁰² ¹²¹⁰

Other hypertension guidelines generally have based target BP goals on age and comorbidities.⁵⁰¹ ⁵⁰⁴ ⁵³⁶ Guidelines such as those issued by the JNC 8 expert panel generally have targeted a BP goal of <140/90 mm Hg regardless of cardiovascular risk and have used higher BP thresholds and target BPs in elderly patients⁵⁰¹ ⁵⁰⁴ compared with those recommended by the 2017 ACC/AHA hypertension guideline.¹²⁰⁰

Some clinicians continue to support previous target BPs recommended by JNC 8 due to concerns about the lack of generalizability of data from some clinical trials (e.g., SPRINT study) used to support the 2017 ACC/AHA hypertension guideline and potential harms (e.g., adverse drug effects, costs of therapy) versus benefits of BP lowering in patients at lower risk of cardiovascular disease.¹²²² ¹²²³ ¹²²⁴ ¹²²⁹

Consider potential benefits of hypertension management and drug cost, adverse effects, and risks associated with the use of multiple antihypertensive drugs when deciding a patient's BP treatment goal.¹²⁰⁰ ¹²²⁰ ¹²²⁹

For decisions regarding when to initiate drug therapy (BP threshold), the 2017 ACC/AHA hypertension guideline incorporates underlying cardiovascular risk factors.¹²⁰⁰ ¹²⁰⁷ ASCVD risk assessment is recommended by ACC/AHA for all adults with hypertension.¹²⁰⁰

ACC/AHA currently recommend initiation of antihypertensive drug therapy in addition to lifestyle/behavioral modifications at an SBP ≥140 mm Hg or DBP ≥90 mm Hg in adults who have no history of cardiovascular disease (i.e., primary prevention) and a low ASCVD risk (10-year risk <10%).¹²⁰⁰

For secondary prevention in adults with known cardiovascular disease or for primary prevention in those at higher risk for ASCVD (10-year risk ≥10%), ACC/AHA recommend initiation of antihypertensive drug therapy at an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg.¹²⁰⁰

Adults with hypertension and diabetes mellitus, chronic kidney disease (CKD), or age ≥65 years are assumed to be at high risk for cardiovascular disease; ACC/AHA state that such patients should have antihypertensive drug therapy initiated at a BP ≥130/80 mm Hg.¹²⁰⁰ Individualize drug therapy in patients with hypertension and underlying cardiovascular or other risk factors.⁵⁰² ¹²⁰⁰

In stage 1 hypertension, experts state that it is reasonable to initiate drug therapy using the stepped-care approach in which one drug is initiated and titrated and other drugs are added sequentially to achieve the target BP.¹²⁰⁰ Initiation of antihypertensive therapy with 2 first-line agents from different pharmacologic classes recommended in adults with stage 2 hypertension and average BP >20/10 mm Hg above BP goal.¹²⁰⁰

Black hypertensive patients generally tend to respond better to monotherapy with calcium-channel blockers or thiazide diuretics than to β-blockers.³⁵⁵ ³⁵⁹ ³⁶⁰ ⁵⁰¹ ⁵⁰⁴ ¹²⁰⁰ However, diminished response to β-blockers is largely eliminated when administered concomitantly with a thiazide diuretic.⁵⁰⁰

Cardiac Arrhythmias

Treatment of frequent ventricular premature complexes (VPCs), including uniform and multiform VPCs and/or coupled VPCs, and R-on-T complexes¹ ² ¹³⁷ ¹⁸⁵ ¹⁸⁶ ¹⁸⁷ ¹⁸⁸ ¹⁸⁹ ¹⁹⁰ ¹⁹³ ¹⁹⁴ ¹⁹⁵ ¹⁹⁶ ¹⁹⁷ ¹⁹⁸ ¹⁹⁹ ²⁰¹ ²⁰⁴ in patients with primary arrhythmias or arrhythmias secondary to various cardiac disorders (e.g., CAD,¹³⁷ ¹⁸⁵ ¹⁸⁶ ¹⁸⁷ ¹⁸⁸ ¹⁸⁹ ¹⁹⁴ acute MI,¹³⁷ ¹⁸⁶ ¹⁸⁷ ¹⁹³ ¹⁹⁴ ¹⁹⁵ ¹⁹⁶ valvular disease).¹⁸⁵ ¹⁸⁶ ¹⁸⁷ ¹⁸⁹ ¹⁹⁰

Management of various supraventricular tachyarrhythmias^{† [off-label]}.¹⁹¹ ¹⁹² ¹⁹⁶ ²⁰⁰ ²⁰² ²⁰³ ²⁵⁶ ²⁶⁶

Angina

Management of chronic stable angina pectoris^{† [off-label]}.²⁰⁵ ²⁰⁶ ²⁰⁷ ²⁰⁸ ²⁰⁹ ²¹⁰ ²¹¹ ²¹² ²¹³ ²¹⁴ ²²⁰ ²²¹ ²²² ²²³ ²²⁴ ²²⁵

Acute MI

Secondary prevention following acute MI^{† [off-label]} to reduce the risk of reinfarction and mortality.²⁸⁹ ²⁹⁰

Acebutolol Dosage and Administration

General

Individualize dosage according to patient response.¹ ² ⁴
β-Adrenergic blocking selectivity diminishes as dosage is increased.¹
If long-term therapy is discontinued, reduce dosage gradually over a period of about 2 weeks.¹ ² (See Abrupt Withdrawal of Therapy under Cautions.)
When substituting another β-blocker for acebutolol, initiate at a comparable dosage without interruption of β-blocker therapy.¹ ²

BP Monitoring and Treatment Goals

Monitor BP regularly (i.e., monthly) during therapy and adjust dosage of the antihypertensive drug until BP controlled.¹²⁰⁰
If unacceptable adverse effects occur, discontinue drug and initiate another antihypertensive agent from a different pharmacologic class.¹²¹⁶
If adequate BP response not achieved with a single antihypertensive agent, either increase dosage of single drug or add a second drug with demonstrated benefit and preferably a complementary mechanism of action (e.g., ACE inhibitor, angiotensin II receptor antagonist, calcium-channel blocker, thiazide diuretic).¹²⁰⁰ ¹²¹⁶ Many patients will require ≥2 drugs from different pharmacologic classes to achieve BP goal; if goal BP still not achieved, add a third drug.¹²⁰⁰ ¹²¹⁶

Administration

Acebutolol hydrochloride is administered orally.¹ ² Also been administered IV^{† [off-label]},²⁵ ²⁷ ²⁸ ²⁹ ⁴¹ ¹⁹¹ ¹⁹² ¹⁹⁶ ²⁰⁰ ²⁰² ²⁰³ ²⁶⁶ but a parenteral dosage form is currently not commercially available in the US.

Oral Administration

Hypertension

Usually administer as a single daily dose;¹ ²⁴⁵ however, for 24-hour BP control, some patients may require administration of the daily dose in 2 divided doses.¹ ¹⁴² ¹⁴³ ¹⁴⁴ ¹⁴⁵ ¹⁴⁹ ¹⁵⁵

Ventricular Arrhythmias

Twice-daily dosing of the drug appears to be more effective than once-daily dosing for the suppression and prevention of frequent VPCs.⁴ ¹⁸⁵ ¹⁸⁶ ¹⁸⁸ ¹⁸⁹ ¹⁹⁵ ¹⁹⁸ ¹⁹⁹ ²⁰³ ²⁰⁴ ²⁴⁸

Angina

Once-daily administration may be as effective as divided doses;⁴ ²⁰⁸ ²⁴⁹ however, further studies are needed.⁴

Dosage

Available as acebutolol hydrochloride; dosage expressed in terms of acebutolol.¹

Adults

Hypertension

Oral

Initially, 200–400 mg daily.¹ ²⁴⁵ ³²¹ Manufacturer and some clinicians state usual maintenance dosage is 400–800 mg daily, ¹ ¹⁴⁰ ¹⁴² ¹⁴³ ¹⁴⁴ ¹⁴⁵ ¹⁴⁹ ¹⁵⁰ ¹⁵¹ ¹⁵² ¹⁵³ ¹⁵⁴ ²⁴⁵ ²⁴⁶ ²⁴⁷ but some patients may achieve adequate BP control with dosages as low as 200 mg daily.¹ ⁴

Increase dosage up to 1.2 g daily in 2 divided doses in patients with more severe hypertension or if adequate reduction of BP does not occur;¹ ² ⁴ ¹⁴⁰ ¹⁴² ¹⁴³ ¹⁴⁴ ¹⁴⁵ ¹⁴⁹ ¹⁵⁰ ¹⁵¹ ¹⁵² ¹⁵⁴ ¹⁵⁵ alternatively, add another hypotensive agent (e.g., thiazide diuretic).¹ ² ⁴ ¹⁴² ¹⁴⁴ ¹⁵⁷ ¹⁵⁸ ¹⁶⁰ ¹⁶¹ ¹⁶⁵ ¹⁶⁶ ¹⁶⁸

Some experts state usual dosage range is 200–800 mg daily, administered in 2 divided doses.¹²⁰⁰

Ventricular Arrhythmias

Oral

Initially, 200 mg twice daily.¹ ¹⁸⁷ ¹⁹⁶ Increase gradually until optimum effect is achieved.¹ ¹⁸⁵ ¹⁸⁶ ¹⁹⁵ ¹⁹⁸ ²⁰⁴ Usual maintenance dosage is 600–1200 mg daily.¹ ² ⁴ ¹⁸⁵ ¹⁸⁶ ¹⁸⁹ ¹⁹⁰ ¹⁹⁵ ¹⁹⁹ ²⁰⁴

Angina

Oral

Initially, 200 mg twice daily.⁴ ²⁰⁵ ²⁰⁸ Increase dosage gradually until optimum effect is achieved.⁴ ²⁰⁵ Usual maintenance dosage is 800 mg or less daily,⁴ ²⁰⁶ ²⁰⁷ ²⁰⁸ ²⁰⁹ ²¹⁰ ²¹¹ ²¹² ²¹³ ²¹⁴ but patients with severe angina may require higher dosages.⁴ ²⁰⁵ ²⁰⁹ ²¹¹

Adjust dosage of β-blockers according to clinical response⁴ ²⁰⁵ and to maintain a resting heart rate of 55–60 bpm.²¹¹ ²¹⁶

Prescribing Limits

Adults

Hypertension

Oral

Maximum 1.2 g daily.¹ ² ⁴ ¹⁴⁰ ¹⁴² ¹⁴³ ¹⁴⁴ ¹⁴⁵ ¹⁴⁹ ¹⁵⁰ ¹⁵¹ ¹⁵² ¹⁵⁴ ¹⁵⁵

Special Populations

Renal Impairment

Active metabolite (diacetolol) eliminated principally by the kidneys;¹ ¹²³ ¹²⁵ dosage and/or frequency of administration must be modified in response to the degree of renal impairment.¹ ² ⁸⁶ ¹²³ ¹²⁴ ¹²⁵ ¹²⁶ ¹²⁷

Dosage Reductions in Patients with Renal Impairment
Reduction in Usual Daily Dosage	Cl_cr (mL/min)
50%	25–49 mL/minute
75%	<25 mL/minute

Acebutolol and diacetolol removed by hemodialysis;¹ ¹²⁵ ¹²⁷ individualize dosage carefully in patients with severe renal impairment who undergo chronic intermittent hemodialysis.¹²⁴ ¹²⁵

Geriatric Patients

Consider reduction in maintenance dosage.¹ ² Avoid dosages >800 mg daily.¹ ²

Cautions for Acebutolol

Contraindications

Patients with heart block greater than first degree, severe bradycardia, cardiogenic shock, or overt cardiac failure.¹

Warnings/Precautions

Warnings

Heart Failure

Possible precipitation of heart failure.¹

Avoid use in patients with decompensated heart failure; use cautiously in patients with inadequate myocardial function and, if necessary, in patients with well-compensated heart failure (e.g., those controlled with cardiac glycosides and/or diuretics).¹

Adequate treatment (e.g., with a cardiac glycoside and/or diuretic) and close observation recommended if signs or symptoms of impending cardiac failure occur; if cardiac failure continues, discontinue therapy, gradually if possible.¹

Abrupt Withdrawal of Therapy

Possible exacerbated angina symptoms or precipitation of MI in patients with CAD.¹ Abrupt discontinuance of therapy is not recommended.¹ ²⁷⁶ Gradually decrease dosage over a period of about 2 weeks; monitor patients carefully and advise to temporarily limit their physical activity.¹ ²⁷⁶ If exacerbation of angina occurs, reinstitute therapy promptly and initiate appropriate measures for the management of unstable angina pectoris.¹

Peripheral Vascular Disease

Possible reduction in cardiac output and precipitation or aggravation of symptoms of arterial insufficiency.¹ Use with caution; observe for evidence of disease progression.¹

Bronchospastic Disease

Possible bronchoconstriction.¹

Use with caution in patients with bronchospastic disease; administer the lowest effective dosage (initially in divided doses). A bronchodilator (e.g., a β₂-adrenergic agonist, theophylline) should be available for immediate use, if necessary.¹

Major Surgery

Possible risks associated with general anesthesia (e.g., severe hypotension, maintenance of heart beat) due to decreased ability of the heart to respond to reflex β-adrenergic stimuli.¹ Use with caution in patients undergoing major surgery involving general anesthesia; anesthetics used should not cause myocardial depression.¹

Diabetes and Hypoglycemia

Possible decreased signs and symptoms of hypoglycemia (e.g., tachycardia, palpitation, BP changes, tremor, feelings of anxiety, but not sweating or dizziness) and increased insulin-induced hypoglycemia.¹

Use with caution in patients with diabetes mellitus.¹

Thyrotoxicosis

Signs of hyperthyroidism (e.g., tachycardia) may be masked.¹ Possible thyroid storm if therapy is abruptly withdrawn; carefully monitor patients having or suspected of developing thyrotoxicosis.¹

Sensitivity Reactions

Anaphylactic Reactions

Patients with a history of anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenges with such allergens while taking β-blocking agents.¹ Such patients may be unresponsive to usual doses of epinephrine.¹

Specific Populations

Pregnancy

Category B.¹

Lactation

Distributed into milk in higher concentrations than in maternal plasma.¹ ² ¹⁰⁵ Use not recommended by manufacturer.¹

Pediatric Use

Safety and efficacy not established in children <12 years of age.¹ ²⁶⁸

Geriatric Use

Insufficient experience in patients >65 years of age to determine whether geriatric patients respond differently than younger adults.¹ However, reduction of maintenance dosage may be necessary,¹ ² since bioavailability of acebutolol and diacetolol (active metabolite) may be increased compared with that in younger adults.¹ ² ¹²² (See Geriatric Patients under Dosage and Administration.)

Hepatic Impairment

Use with caution.¹ ² Cirrhosis does not appear to substantially affect the pharmacokinetics of acebutolol or diacetolol; however, the effects of hepatic impairment on elimination of the drug have not been fully evaluated.¹²⁸

Renal Impairment

Use with caution; dosage should be reduced based on the degree of renal impairment.¹ (See Renal Impairment under Dosage and Administration.)

Common Adverse Effects

Fatigue, dizziness, headache, dyspnea, constipation, diarrhea, dyspepsia, nausea, flatulence, insomnia, increased micturition, chest pain, edema, depression, abnormal dreams, rash, arthralgia, myalgia, cough, rhinitis, abnormal vision.¹

Drug Interactions

Specific Drugs

Drug	Interaction	Comments
α-Adrenergic agonists¹	Possible exaggerated hypertensive reactions¹	Warn patients of potential hazard¹
Calcium-channel blockers	Potential additive depressant effects on SA or AV nodal conduction³¹⁸ ³¹⁹
Cardiac glycosides (digoxin)	Potential additive depressant effects on SA or AV nodal conduction³¹⁸ ³¹⁹ Pharmacokinetic interaction unlikely¹
Diuretics	Possible increased hypotensive effect¹ ² ¹⁴² ¹⁴⁴ ¹⁵⁷ ¹⁵⁸ ¹⁶⁰	Careful dosage adjustment recommended¹ ² ¹⁴⁴ ¹⁵⁷ ¹⁵⁸ ¹⁶⁰
Glyburide	Possible decreased hypoglycemic action in type II diabetic patients, presumably by decreasing insulin secretion²⁴⁴
Hydralazine	Pharmacokinetic interaction unlikely¹
Hydrochlorothiazide	Pharmacokinetic interaction unlikely¹
Hypotensive agents	Possible increased hypotensive effect¹ ² ¹⁴² ¹⁴⁴ ¹⁵⁷ ¹⁵⁸ ¹⁶⁰	Careful dosage adjustment recommended¹ ² ¹⁴⁴ ¹⁵⁷ ¹⁵⁸ ¹⁶⁰
NSAIAs	Potential blunting of hypotensive effects¹
Oral contraceptives	Pharmacokinetic interaction unlikely¹
Reserpine	Possible additive pharmacologic effects¹	Observe closely for evidence of marked bradycardia or hypotension (e.g., vertigo, presyncope or syncope, or orthostatic changes in BP without compensatory tachycardia)¹
Sulfinpyrazone	Pharmacokinetic interaction unlikely¹
Sympathomimetic agents	Antagonism of β₁-adrenergic stimulating effects (e.g., bronchodilation)¹ ² ⁵⁷ ⁵⁸ ⁵⁹ ⁶²	Increased dosage of β-adrenergic agonist bronchodilators may be required ²⁶⁸ ²⁷⁷
Tolbutamide	Interaction unlikely¹
Warfarin	Interaction unlikely¹

Acebutolol Pharmacokinetics

Absorption

Bioavailability

Well absorbed from the GI tract following oral administration;¹ ² ⁴ ¹¹ ⁹¹ ¹⁰⁹ undergoes extensive first-pass metabolism in the liver.¹ ² ⁹⁷ ⁹⁹ ¹⁰⁹ ¹²² ¹²⁴

Peak plasma acebutolol and diacetolol concentrations occur within 2–2.5 hours (range: 1–4 hours) and 4 hours (range: 2.4–5 hours), respectively, in healthy individuals¹ ² ⁹⁴ ⁹⁵ ⁹⁷ ⁹⁸ ⁹⁹ ¹²⁶ ¹³⁵ or patients with hypertension⁹¹ or arrhythmias.² ⁹⁰ ¹³⁷

Absolute bioavailability is approximately 35–50%.¹ ⁴ ⁹⁴ ⁹⁷ ¹⁰²

Food

Food may slightly decrease the rate of absorption and peak plasma concentrations of acebutolol and its major metabolite (diacetolol), but the extent of absorption is not substantially affected.¹ ² ¹⁰¹

Onset

Effect on resting, reflex, or exercise-induced heart rate and systolic BP begins within 1–1.5 hours,¹ ³ ²¹ ⁹¹ ¹⁰⁰ in healthy¹ ²¹ ⁹⁸ ¹⁰⁰ or hypertensive⁹¹ individuals.

Duration

Effect may persist for up to 24 hours or longer.¹ ³ ⁹¹ ⁹⁸ ¹⁰⁰

Special Populations

In geriatric patients, peak plasma concentrations and AUCs of acebutolol and diacetolol are increased twofold compared with those observed in younger patients.¹ ² ¹²²

Distribution

Extent

Acebutolol and diacetolol readily cross the placenta¹ ² ¹⁰⁵ ¹⁰⁶ ¹⁰⁷ and can accumulate in the fetus.¹⁰⁵ ¹⁰⁶ ¹⁰⁷

Acebutolol and diacetolol are distributed into milk at concentrations higher than those in maternal plasma. (See Lactation under Cautions.)¹ ² ¹⁰⁵ ¹⁰⁶

Plasma Protein Binding

Approximately 11–25% (acebutolol) and 6–9% (diacetolol).² ⁹³ ¹⁰³ Approximately 50% bound to erythrocytes.⁴ ¹²⁵

Elimination

Metabolism

Rapidly and extensively metabolized in the liver² ¹¹⁰ ¹¹³ to metabolites (acetolol and diacetolol).² ⁴ ⁶ ⁹⁹ ¹⁰⁸ ¹⁰⁹ ¹¹⁰ ¹¹³

Elimination Route

Acebutolol and its metabolites are excreted in feces and urine.¹ ⁸⁷ ⁹² ¹⁰⁹ ¹¹¹ ¹²³

Half-life

About 3 hours in the initial distribution phase (t_½α) ⁹⁵ and about 11 hours (range: 6–12 hours) in the terminal phase (t_½β).⁹⁵ ¹²⁵ About 7.5 (range: 7–11 hours) and 3 hours, respectively, for diacetolol and acetolol following a single oral dose.¹⁰¹ ¹⁰⁸ ¹²⁵

Special Populations

Renal impairment may reduce clearances of acebutolol and diacetolol.¹²⁵ Acebutolol and diacetolol are removed by hemodialysis.¹ ¹²⁵ ¹²⁷

Stability

Storage

Oral

Capsules

Tight containers¹ ²⁵³ at room temperature (approximately 25°C).¹ ² ³

Protect from light.¹ ³⁰⁵

Actions

Pharmacologic effects result from both the unchanged drug and diacetolol, ¹ ² ¹¹⁴ ¹¹⁵ ¹¹⁶ ¹¹⁷ which is equipotent to acebutolol.¹ ² ¹¹⁴ ¹¹⁵ ¹¹⁶ ¹¹⁷
Inhibits response to adrenergic stimuli by competitively blocking β₁-adrenergic receptors within the myocardium.¹ ² ⁴ ⁵ ⁶ ⁷ ⁸ ⁹ ¹⁰ ¹¹ ¹² ¹³ ¹⁴ ¹⁵ ¹⁶ ¹⁷ ¹⁸ ¹⁹ ²⁰ ²¹ ²² ²³ ²⁴ ²⁵ ²⁶ ²⁷ ²⁸ ³⁴ ³⁵ ³⁶ ³⁷ ³⁸ Blocks β₂-adrenergic receptors within bronchial and vascular smooth muscle only at high doses.⁴ ²⁴ ³⁵ ¹⁷⁸
Decreases exercise-induced heart rate,¹ ² ⁴ ¹¹ ¹² ¹³ ²³ ²⁴ ²⁵ ²⁷ inhibits reflex orthostatic tachycardia,¹ ² ⁴ ¹¹ ¹² ¹³ ²³ ²⁴ and may decrease¹ ² ²⁵ ²⁸ ²⁹ ¹⁴⁰ ¹⁹³ or leave unchanged ²⁶ ¹⁴⁰ cardiac output at rest² ²⁵ ¹⁴⁰ ¹⁹³ or during exercise.¹ ²⁸ ²⁹ Decreases systolic and diastolic BP at rest¹ ² ¹³ ¹⁹ ²³ ⁵⁶ ⁵⁷ ¹³⁹ and during exercise.¹ ² ¹⁵⁵ ¹⁶⁰ ¹⁷¹
Precise mechanism of hypotensive action has not been determined.⁷ ²² ²⁶ ³⁴ ³⁵ ¹³⁹ ¹⁷⁸ May reduce BP by blocking peripheral (especially cardiac) adrenergic receptors (decreasing cardiac output), by decreasing sympathetic outflow from the CNS, and/or by suppressing renin release.⁷ ²⁶ ³⁴ ³⁵ ¹⁴⁰
Exhibits antiarrhythmic activity;¹ ² ¹³⁷ ¹⁸⁵ ¹⁸⁶ ¹⁸⁷ ¹⁸⁸ ¹⁸⁹ ¹⁹⁰ ¹⁹³ ¹⁹⁴ ¹⁹⁵ ¹⁹⁶ ¹⁹⁹ ²⁰⁴ considered a class II antiarrhythmic agent.²⁵⁴
Can produce nervous system effects,¹ ² ⁴ ⁶ ¹⁵⁰ ¹⁵² ¹⁵⁴ ¹⁵⁸ ¹⁷⁰ ¹⁹⁸ although the frequency and/or severity of such effects may be less than those observed with some other β-blockers.¹⁵² ¹⁵⁴ ¹⁵⁶ ²⁶²
Unlike some β-blockers,¹⁴⁷ ¹⁴⁸ does not consistently suppress plasma renin activity (PRA).²⁶ ⁷¹ ¹³⁹ ¹⁴⁰ ¹⁴¹ ¹⁴² ¹⁴³
May increase airway resistance and decrease ventilatory capacity,⁵¹ ⁵² ⁵³ ⁵⁴ ⁵⁷ ⁵⁸ ⁵⁹ ⁶⁰ ⁶¹ ⁶² ⁶³ ⁶⁴ ¹⁵⁵ ¹⁵⁸ especially in patients with asthma and/or COPD or when high dosages are used.⁵² ⁵³ ⁵⁷ ⁵⁸ ⁵⁹ ⁶⁰ ⁶¹ ⁶² ⁶³ ⁶⁴ ¹⁵⁸ ²⁶⁸
Does not appear to substantially affect glucose metabolism;⁷³ ⁷⁵ however, the drug may potentiate insulin-induced hypoglycemia in diabetic patients receiving oral hypoglycemic agents.⁷⁴ (See Interactions.)

Advice to Patients

Importance of taking acebutolol exactly as prescribed.¹
Importance of not interrupting or discontinuing therapy without consulting clinician; patients should temporarily limit physical activity when discontinuing therapy.¹ ²⁷⁶
Importance of immediately informing clinician at the first sign or symptom of impending cardiac failure (e.g., weight gain, increased shortness of breath) or if any difficulty in breathing occurs.¹
In patients with heart failure, importance of informing clinician of signs or symptoms of exacerbation (e.g., weight gain, difficulty in breathing).¹
Importance of patients informing anesthesiologist or dentist that they are receiving acebutolol therapy prior to undergoing major surgery.¹
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.¹
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.¹
Importance of informing patients of other important precautionary information.¹ (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Acebutolol Hydrochloride
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Capsules	200 mg (of acebutolol)*	Acebutolol Hydrochloride Capsules
			Sectral	Promius
		400 mg (of acebutolol)*	Acebutolol Hydrochloride Capsules
			Sectral	Promius

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Wyeth-Ayerst Laboratories. Sectral (acebutolol hydrochloride) prescribing information. In: Physicians’ desk reference. 53rd ed. Montvale, NJ: Medical Economics Company Inc; 1999:3381-3.

2. Ives Laboratories Inc. Sectral product monograph. New York, NY; 1985 Mar.

3. Ives Laboratories Inc. Sectral product information form for American Hospital Formulary Service. Philadelphia, PA; 1985 Jan.

4. Singh BN, Thoden WR, Ward A. Acebutolol: a review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia. Drugs. 1985; 29:531-69. https://pubmed.ncbi.nlm.nih.gov/3891306

5. Cowling CGD, Leary WP. Acebutolol: a review. Curr Ther Res. 1981; 30:765-74.

6. De Bono G, Kaye CM, Roland E et al. Acebutolol: ten years of experience. Am Heart J. 1985; 109(5 Part 2):1211-24. https://pubmed.ncbi.nlm.nih.gov/2859785

7. Anon. Acebutolol. Med Lett Drugs Ther. 1985; 27:58-60. https://pubmed.ncbi.nlm.nih.gov/3892259

8. Abernethy DR, Arendt RM, Greenblatt DJ. Pharmacologic properties of acebutolol: relationship of hydrophilicity to central nervous system penetration. Am Heart J. 1985; 109(5 Part 2):1120-5. https://pubmed.ncbi.nlm.nih.gov/2859774

9. Ryan JR. Clinical pharmacology of acebutolol. Am Heart J. 1985; 109(5 Part 2):1131-6. https://pubmed.ncbi.nlm.nih.gov/2859776

10. Mimnaugh MN, Gearien JE. Adrenergic drugs. In: Foye WO, ed. Principles of medicinal chemistry. 2nd ed. Philadelphia: Lea & Febiger; 1981:377-93.

11. Maxwell DR, Collins RF. Acebutolol (Sectral): I—review of the pharmacology and pharmacokinetics. Clin Trials J. 1974; 11(Suppl 3):9-18.

12. Basil B, Jordan R, Loveless AH et al. β-Adrenoceptor blocking properties and cardioselectivity of M & B 17,803A. Br J Pharmacol. 1973; 48:198-211. https://pubmed.ncbi.nlm.nih.gov/4147427 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1776183/

13. Daly MJ, Flook JJ, Levy GP. The selectivity of β-adrenoceptor antagonists on cardiovascular and bronchodilator responses to isoprenaline in the anaesthetized dog. Br J Pharmacol. 1975; 53:173-81. https://pubmed.ncbi.nlm.nih.gov/238697 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1666304/

14. Harms HH. Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors. J Pharmacol Exp Ther. 1976; 199:329-35. https://pubmed.ncbi.nlm.nih.gov/10427

15. Baird JRC, Linnell J. The assessment of β-adrenoceptor blocking potency and cardioselectivity in vitro and in vivo. J Pharm Pharmacol. 1972; 24:880-5.

16. Harms HH, Spoelstra AJG. Cardiac and bronchial β-adrenoceptor antagonistic potencies of atenolol, metoprolol, acebutolol, practolol, propranolol and pindolol in the anaesthetized dog. Clin Exp Pharmacol Physiol. 1978; 5:53-9. https://pubmed.ncbi.nlm.nih.gov/25152

17. Briant RH, Dollery CT, George CF. Cardiac and peripheral vascular beta-receptors in the dog and in man: the selectivity of acebutolol (Sectral). Clin Trials J. 1974; 11(Suppl 3):25-8.

18. Bilski A, Robertson HH, Wale JL. A study of the relationship between cardiac β-adrenoceptor blockade and intrinsic sympathomimetic activity in rats depleted of catecholamines. Clin Exp Pharmacol Physiol. 1979; 6:1-9. https://pubmed.ncbi.nlm.nih.gov/32980

19. Levy B. The selective beta receptor blocking properties of DL-1-(2-acetyl-4-n-butyramidophenoxy)-2-hydroxy-3- isopropylaminopropane-HCl (M&B 17803-A) in the anesthetized dog. J Pharmacol Exp Ther. 1973; 186:134-44. https://pubmed.ncbi.nlm.nih.gov/4146701

20. Dreyer AC, Offermeier J. In vitro assessment of the selectivities of various beta-adrenergic blocking agents. Life Sci. 1980; 27:2087-92. https://pubmed.ncbi.nlm.nih.gov/6111008

21. Cuthbert MF, Owusu-Ankomah K. Effect of M & B 17803A, a new β-adrenoceptor blocking agent, on the cardiovascular responses to tilting and to isoprenaline in man. Br J Pharmacol. 1971; 43:639-48. https://pubmed.ncbi.nlm.nih.gov/4400530 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1665788/

22. Giacomini JC, Thoden WR. Ancillary pharmacologic properties of acebutolol: cardioselectivity, partial agonist activity, and membrane-stabilizing activity. Am Heart J. 1985; 109(5 Part 2):1137-44. https://pubmed.ncbi.nlm.nih.gov/2859777

23. Wollam GL, Cody RJ Jr, Tarazi RC et al. Acute hemodynamic effects and cardioselectivity of acebutolol, practolol, and propranolol. Clin Pharmacol Ther. 1979; 25:813-20. https://pubmed.ncbi.nlm.nih.gov/445948

24. Mougeot G, Hugues FC, Julien D et al. Influence of propranolol and acebutolol on isoprenaline-induced changes in heart rate and peripheral blood flow in man. Arch Int Pharmacodyn Ther. 1981; 251:116-25. https://pubmed.ncbi.nlm.nih.gov/7259364

25. Svendsen TL, Trap-Jensen J, C et al. Immediate central hemodynamic effects of five different beta-adrenoceptor-blocking agents, acebutolol, atenolol, pindolol, practolol, and propranolol, in patients with ischemic heart disease. Am Heart J. 1985; 109(5 Part 2):1145-50. https://pubmed.ncbi.nlm.nih.gov/2859778

26. Dreslinski GR, Aristimuno GG, Messerli FH et al. Effects of beta blockade with acebutolol on hypertension, hemodynamics, and fluid volume. Clin Pharmacol Ther. 1979; 26:562-5. https://pubmed.ncbi.nlm.nih.gov/498697

27. Nigri A, Mangieri E, Martuscelli E et al. Acute hemodynamic effects of acebutolol and propranolol. Clin Ther. 1984; 6:693-8. https://pubmed.ncbi.nlm.nih.gov/6478471

28. Dalal JJ, Ross PJ, Wong K et al. Acute effects of acebutolol on cardiovascular function in man. Br J Clin Pharmacol. 1981; 11:265-8. https://pubmed.ncbi.nlm.nih.gov/7213527 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1401624/

29. Mason JW, Specter MJ, Ingels NB et al. Haemodynamic effects of acebutolol. Br Heart J. 1978; 40:29-34. https://pubmed.ncbi.nlm.nih.gov/341929 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC481970/

30. Lewis BS, Bakst A, Mitha AS et al. Haemodynamic effects of a new beta-blocking agent ″Sectral’ (M & B 17803A). Br Heart J. 1973; 35:743-51. https://pubmed.ncbi.nlm.nih.gov/4146280 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC458693/

31. Ireland MA, Littler WA. The effects of oral acebutolol and propranolol on forearm blood flow in hypertensive patients. Br J Clin Pharmacol. 1981; 12:363-8. https://pubmed.ncbi.nlm.nih.gov/7295466 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1401805/

32. Joye JA, Lee G, DeMaria AN et al. Afterload advantage of cardioselective beta blockade by acebutolol versus propranolol: hemodynamic assessment by cardiac catheterization in coronary patients. Circulation. 1978; 58:153. https://pubmed.ncbi.nlm.nih.gov/647879

33. Ablad B, Brogard M, C et al. β-Adrenergic receptor blocking properties of three allyl-substituted phenoxypropanolamines. Eur J Pharmacol. 1970; 13:59-64. https://pubmed.ncbi.nlm.nih.gov/4395676

34. Prichard BNC. β-Adrenergic receptor blockade in hypertension, past, present and future. Br J Clin Pharmacol. 1978; 5:379-99. https://pubmed.ncbi.nlm.nih.gov/26370 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429347/

35. Thadani U. Beta blockers in hypertension. Am J Cardiol. 1983; 52:10-5D.

36. Conolly ME, Kersting F, Dollery CT. The clinical pharmacology of beta-adrenoceptor-blocking drugs. Prog Cardiovasc Dis. 1976; 19:203-34. https://pubmed.ncbi.nlm.nih.gov/10600

37. Shand DG. State-of-the-art: comparative pharmacology of the β-adrenoceptor blocking drugs. Drugs. 1983; 25(Suppl 2):92-9.

38. Breckenridge A. Which beta blocker? Br Med J. 1983; 286:1085-8. (IDIS 169422)

39. Waal-Manning HHJ. The antihypertensive action of several β-adrenoceptor-blocking drugs. N Z Med J. 1976; 83:223-6. https://pubmed.ncbi.nlm.nih.gov/8748

40. LeClercq JF, Rosengarten MD, Kural S et al. Effects of intrinsic sympathetic activity of beta-blockers on SA and AV nodes in man. Eur J Cardiol. 1981; 12:367-75. https://pubmed.ncbi.nlm.nih.gov/6113145

41. Marrott PK, Ruttley ST, Jenkins PM et al. The electrophysiological evaluation of intravenous acebutolol, a β-blocking drug. Eur J Cardiol. 1977; 6:117-30. https://pubmed.ncbi.nlm.nih.gov/913484

42. Amlie JP, Lessum S, Collins RF et al. Plasma levels and electrophysiological effects of acebutolol (M & B 17.803) in the dog heart in situ. Acta Pharmacol Toxicol. 1977; 40:378-88.

43. Kaul S, Hecht HS, Seidman R et al. Comparative effects of oral acebutolol and propranolol at rest and during exercise in ischemic heart disease: double-blind placebo crossover study utilizing radionuclide ventriculography. Am Heart J. 1984; 108:469-74. https://pubmed.ncbi.nlm.nih.gov/6382987

44. Rochette L, Didier JP, Moreau D et al. Role of beta-adrenoceptor antagonism in the prevention of reperfusion ventricular arrhythmias: effects of acebutolol, atenolol, and d-propranolol on isolated working rat hearts subject to myocardial ischemia and reperfusion. Am Heart J. 1984; 107:1132-41. https://pubmed.ncbi.nlm.nih.gov/6144264

45. Mason JW, Winkle RA, Meffin PJ et al. Electrophysiological effects of acebutolol. Br Heart J. 1978; 40:35-40. https://pubmed.ncbi.nlm.nih.gov/341930 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC481971/

46. Touboul P, Huerta F, Porte J et al. Etude des proprietes electrophysiologiques de l’acebutolol chez l’homme. (French; with English abstract.) Therapie. 1975; 30:417-27.

47. Chandraratna PAN, Aronow WS, Laddu A. Effects of acebutolol and propranolol on left ventricular performance assessed by echocardiography. Clin Pharmacol Ther. 1980; 27:460-3. https://pubmed.ncbi.nlm.nih.gov/7357803

48. Katz RJ, DiBianco R, Singh S et al. Acebutolol and left ventricular function: assessment by radionuclide angiography. Clin Pharmacol Ther. 1981; 29:149-54. https://pubmed.ncbi.nlm.nih.gov/7460480

49. Maclagan J, Ney UM. A comparison of the bronchoconstrictor and β-adrenoceptor blocking activity of propranolol and acebutolol. Br J Pharmacol. 1980; 68:196-8. https://pubmed.ncbi.nlm.nih.gov/6101978 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2043927/

50. Wood AJJ. Pharmacologic differences between beta blockers. Am Heart J. 1984; 108:1070-7. https://pubmed.ncbi.nlm.nih.gov/6148865

51. Kumana CR, Kaye CM, Leighton M et al. Cardiac and pulmonary effects of acebutolol. Lancet. 1975; 5:89-93.

52. Benson MK, Berrill WT, Cruickshank JM et al. A comparison of four β-adrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol. 1978; 5:415-9. https://pubmed.ncbi.nlm.nih.gov/26371 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429350/

53. Nair S, Maguire WC, Laddu AR. The effect of acebutolol, a beta adrenergic blocking agent, and placebo on pulmonary functions in asthmatics. Int J Clin Pharmacol Ther Toxicol. 1981; 19:519-26.

54. Gribbin HR, Mackay AD, Baldwin CJ et al. Bronchial and cardiac β-adrenoceptor blockade—a comparison of atenolol, acebutolol and labetalol. Br J Clin Pharmacol. 1981; 12:61-5. https://pubmed.ncbi.nlm.nih.gov/6264936 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1401756/

55. Mue S, Sasaki T, Ohmi T et al. Influence of acebutolol on the haemodynamic and respiratory function of asthmatic patients. J Pharmacother. 1979; 2:67-71.

56. DiBianco R, Dickie KJ, Singh S et al. Pulmonary effects of acebutolol, a “cardioselective” beta adrenergic blocking agent. Int J Clin Pharmacol Ther Toxicol. 1982; 20:1-7. https://pubmed.ncbi.nlm.nih.gov/6120142

57. Greefhorst APM, van Herwaarden CLA. Ventilatory and haemodynamic effects of terbutaline infusion during beta₁-selective blockade with metoprolol and acebutolol in asthmatic patients. Eur J Clin Pharmacol. 1982; 23:203-8. https://pubmed.ncbi.nlm.nih.gov/6756931

58. Whitsett TL, Levin DC, Manion CV. Comparison of the beta₁ and beta₂ adrenoceptor blocking properties of acebutolol and propranolol. Chest. 1982; 82:668-73. https://pubmed.ncbi.nlm.nih.gov/6128186

59. Greefhorst APM, van Herwaarden CLA. Comparative study of the ventilatory effects of three beta₁-selective blocking agents in asthmatic patients. Eur J Clin Pharmacol. 1981; 20:417-21. https://pubmed.ncbi.nlm.nih.gov/6116610

60. Leary WP, Coleman AJ, Asmal AC. Respiratory effects of acebutolol hydrochloride: a new selective beta-adrenergic blocking agent. S Afr Med J. 1973; 47:1245-8. https://pubmed.ncbi.nlm.nih.gov/4146466

61. Skinner C, Palmer KNV, Kerridge DF. Comparison of the effects of acebutolol (Sectral) and practolol (Eraldin) on airways obstruction in asthmatics. Br J Clin Pharmacol. 1975; 2:417-22. https://pubmed.ncbi.nlm.nih.gov/786353 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1402628/

62. Skinner C, Palmer KNV. Airways obstruction in asthmatic patients: comparison of the effects of acebutolol, practolol and placebo. Clin Trials J. 1974; 11:29-32.

63. Palmer KNV. Respiratory side effects of beta-blockers. Br Med J. 1977; 1:841.

64. Decalmer PBS, Chatterjee SS, Cruickshank JM et al. Beta-blockers and asthma. Br Heart J. 1978; 40:184-9. https://pubmed.ncbi.nlm.nih.gov/25075 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC482795/

65. Freed E. Acebutolol-controlled tachycardia in a depressed asthmatic. Med J Aust. 1980; 1:442.

66. Tattersfield AE, Harrison RN. Effect of β-blocker therapy on airway function. Drugs. 1983; 25(Suppl 2):227-31.

67. Gibbons DO, Lant AF, Ashford A et al. Comparative effects of acebutolol and practolol on the lipolytic response to isoprenaline. Br J Clin Pharmacol. 1976; 3:177-84. https://pubmed.ncbi.nlm.nih.gov/973938 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1428816/

68. Newman RJ. Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia. Br Med J. 1976; 2:447-9. https://pubmed.ncbi.nlm.nih.gov/8187 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1687571/

69. Lehtonen A. The effect of acebutolol on plasma lipids, blood glucose and serum insulin levels. Acta Med Scand. 1984; 216:57-60. https://pubmed.ncbi.nlm.nih.gov/6385635

70. Grimaldi A, Bennett P, Delas B et al. β-Blockers and hypoglycaemia (assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia). Curr Ther Res. 1984; 36:361-73.

71. Covi G, Dalla Riva AD, Pomari S et al. Long-term treatment of essential hypertension with acebutolol: an evaluation of clinical and metabolic effects. Curr Ther Res. 1982; 31:1018-25.

72. Birnbaum J, DiBianco R, Becker KL et al. Glucose and lipid metabolism during acebutolol and propranolol therapy of angina in nondiabetic patients. Clin Pharmacol Ther. 1983; 33:294-300. https://pubmed.ncbi.nlm.nih.gov/6337762

73. Frances Y, Luccioni R, Vague P et al. Effects of betaxolol, propranolol, and acebutolol on the glycoregulation after oral glucose tolerance test in hypertensive patients. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:213-20.

74. Deacon SP, Karunanayake A, Barnett D. Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics. Br Med J. 1977; 2:1255-7. https://pubmed.ncbi.nlm.nih.gov/338101 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1632423/

75. Koch G, Franz IW, Gubba A et al. β-Adrenoceptor blockade and physical activity: cardiovascular and metabolic aspects. Acta Med Scand. 1983; 672(Suppl):55-62.

76. Barnett AH, Leslie D, Watkins PJ. Can insulin-treated diabetics be given beta-adrenergic blocking drugs? Br Med J. 1980; 280:976-8.

77. Leary WP. The cardioselectivity of acebutolol (Sectral) in man. Clin Trials J. 1974; 11(Suppl 3):33-5.

78. James I. The beta-blocker dilemma. Geriatric Med. 1983; 13:429-30.

79. Giuntoli F, Scalabrino A, Galeone F et al. Antihypertensive and metabolic effects of a long-term treatment with acebutolol. Curr Ther Res. 1984; 36:188-94.

80. Newman RJ. Comparison of the antilipolytic effect of metoprolol, acebutolol, and propranolol in man. Br Med J. 1977; 2:601-3. https://pubmed.ncbi.nlm.nih.gov/901996 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1631536/

81. Lehtonen A. Effect of beta blockers on blood lipid profile. Am Heart J. 1985; 109(5 Part 2):1192-6. https://pubmed.ncbi.nlm.nih.gov/2859784

82. Harms HH, Gooren L, Spoelstra AJG et al. Blockade of isoprenaline-induced changes in plasma free fatty acids, immunoreactive insulin levels and plasma renin activity in healthy human subjects, by propranolol, pindolol, practolol, atenolol, metoprolol and acebutolol. Br J Clin Pharmacol. 1978; 5:19-26. https://pubmed.ncbi.nlm.nih.gov/23133 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429223/

83. Lewis MJ, Groom GV, Barber R et al. The effects of propranolol and acebutolol on the overnight plasma levels of anterior pituitary and related hormones. Br J Clin Pharmacol. 1981; 12:737-42. https://pubmed.ncbi.nlm.nih.gov/6800389 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1401950/

84. Jones MK, John R, Jones GR. The effect of oxprenolol, acebutolol and propranolol on thyroid hormones in hyperthyroid subjects. Clin Endocrinol. 1980; 13:343-7.

85. Collett JT, Hendrickson JA, Chew YC et al. Comparative beta-blocking potencies of acebutolol and propranolol relative to plasma drug levels. Int J Clin Pharmacol Ther Toxicol. 1981; 19:473-8. https://pubmed.ncbi.nlm.nih.gov/6117519

86. de Villiers AS, Folb PI, Pascoe M et al. Pharmacokinetics of acebutolol and its acetyl metabolite, diacetolol, in hypertensive patients and in renal use. S Afr J Sci. 1981; 77:286.

87. George CF, Gruchy BS. Elimination of drugs by active intestinal transport. J Pharm Pharmacol. 1979; 31:643-4. https://pubmed.ncbi.nlm.nih.gov/41074

88. Cockburn JJ. Which beta blocker? Br Med J. 1983; 286:1439. Letter.

89. Feely J, Maclean D. New drugs: beta blockers and sympathomimetics. BMJ. 1983; 286:1972. https://pubmed.ncbi.nlm.nih.gov/6407660 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1548319/

90. Winkle RA, Meffin PJ, Ricks WB et al. Acebutolol metabolite plasma concentration during chronic oral therapy. Br J Clin Pharmacol. 1977; 4:519-22. https://pubmed.ncbi.nlm.nih.gov/911602 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429145/

91. Martin MA, Phillips FC, Tucker GT et al. Acebutolol in hypertension: relationships between drug concentration and effects. Eur J Clin Pharmacol. 1978; 14:383-90. https://pubmed.ncbi.nlm.nih.gov/367793

92. Kaye CM. The biliary excretion of acebutolol in man. J Pharm Pharmacol. 1976; 28:449-50. https://pubmed.ncbi.nlm.nih.gov/6757

93. Meffin PJ, Winkle RA, Peters FA et al. Acebutolol disposition after intravenous administration. Clin Pharmacol Ther. 1977; 22:557-67. https://pubmed.ncbi.nlm.nih.gov/913023

94. Meffin PJ, Winkle RA, Peters FA et al. Dose-dependent acebutolol disposition after oral administration. Clin Pharmacol Ther. 1978; 24:542-7. https://pubmed.ncbi.nlm.nih.gov/699478

95. Gulaid AA, James IM, Kaye CM et al. The pharmacokinetics of acebutolol in man, following the oral administration of acebutolol HCl as a single dose (400 mg), and during and after repeated oral dosing (400 mg, b.d.) Biopharm Drug Dispos. 1981; 2:103-14.

96. de Soyza ND, Murphy ML, O’Riley M et al. Correlation of antiarrhythmic activity of acebutolol with blood levels and heart rate. Clin Pharmacol Ther. 1982; 31:217.

97. Roux A, Flouvat B, Fouache Y et al. Systemic bioavailability of acebutolol in man. Biopharm Drug Dispos. 1983; 4:293-7. https://pubmed.ncbi.nlm.nih.gov/6626703

98. Cuthbert MF, Collins RF. Plasma levels and β-adrenoceptor blockade with acebutolol, practolol and propranolol in man. Br J Clin Pharmacol. 1975; 2:49-55. https://pubmed.ncbi.nlm.nih.gov/1234486 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1402490/

99. Meffin PJ, Harapat SR, Harrison DC. Quantitation in plasma and urine of acebutolol and a major metabolite with preliminary observations on their disposition kinetics in man. Res Commun Chem Pathol Pharmacol. 1976; 15:31-51. https://pubmed.ncbi.nlm.nih.gov/968178

100. Watson RDS, Littler WA. Onset and duration of β-adrenergic receptor blockade following single oral dose acebutolol hydrochloride (Sectral). Br J Clin Pharmacol. 1979; 7:557-61. https://pubmed.ncbi.nlm.nih.gov/37868 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429672/

101. Zaman R, Wilkins MR, Kendall MJ et al. The effect of food and alcohol on the pharmacokinetics of acebutolol and its metabolite, diacetolol. Biopharm Drug Dispos. 1984; 5:91-5. https://pubmed.ncbi.nlm.nih.gov/6704510

102. Kaye CM, Kumana CR, Leighton M et al. Observations on the pharmacokinetics of acebutolol. Clin Pharmacol Ther. 1976; 19:416-20. https://pubmed.ncbi.nlm.nih.gov/1269192

103. Coombs TJ, Coulson CJ, Smith VJ. Blood plasma binding of acebutolol and diacetolol in man. Br J Clin Pharmacol. 1980; 9:395-7. https://pubmed.ncbi.nlm.nih.gov/7378256 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429991/

104. Zaman R, Jack DB, Kendall MJ. The penetration of acebutolol and its major metabolite, diacetolol, into human cerebrospinal fluid and saliva. Br J Clin Pharmacol. 1981; 12:427-9. https://pubmed.ncbi.nlm.nih.gov/7295474 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1401814/

105. Bianchetti G, Boutroy MJ, Dubruc C et al. Placental transfer and pharmacokinetics of acebutolol and N-acetyl acebutolol in the newborn. Br J Pharmacol. 1981; 72:135-6P.

106. Bianchetti G, Dubruc C, Vert P et al. Placental transfer and pharmacokinetics of acebutolol in newborn infants. Clin Pharmacol Ther. 1981; 29:233-4.

107. Daffos F, Freund M, Sarrot G et al. Passage transplacentaire de l’acebutolol et du diacetolol. Nouv Presse Med. 1982; 11:2154-5.

108. Alexander MS, Bianchine JR. Acebutolol kinetics following oral and intravenous administration in man. Clin Pharmacol Ther. 1984; 35:225.

109. Gabriel R, Kaye CM, Sankey MG. Preliminary observations on the excretion of acebutolol and its acetyl metabolite in the urine and faeces of man. J Pharm Pharmacol. 1981; 33:386-7. https://pubmed.ncbi.nlm.nih.gov/6115014

110. Andresen BD, Davis FT. Metabolism of acebutolol-d₆ in the rat correlates with the identification of a new metabolite in human urine. Drug Metab Dispos. 1979; 79:360-5.

111. Collins RF, George CF. Studies on the disposition and fate of [¹⁴C]-acebutolol in man and dog. Br J Clin Pharmacol. 1976; 3:346-7P.

112. Roux A, Flouvat B, Chau NP et al. Pharmacokinetics of acebutolol after intravenous bolus administration. Br J Clin Pharmacol. 1980; 9:215-7. https://pubmed.ncbi.nlm.nih.gov/7356910 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429864/

113. Gulaid A, James IM, Kaye CM et al. Lack of correlation between acetylator status and the production of the acetyl metabolite of acebutolol in man. Br J Clin Pharmacol. 1978; 5:261-2. https://pubmed.ncbi.nlm.nih.gov/656272 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429267/

114. Basil B, Jordan R. Pharmacological properties of diacetolol (M&B 16,942), a major metabolite of acebutolol. Eur J Pharmacol. 1982; 80:47-56. https://pubmed.ncbi.nlm.nih.gov/6124437

115. Thomas MS, Tattersfield AE. Comparison of beta-adrenoceptor selectivity of acebutolol and its metabolite diacetolol with metoprolol and propranolol in normal man. Eur J Clin Pharmacol. 1986; 29:679-83. https://pubmed.ncbi.nlm.nih.gov/2872056

116. Ohashi K, Warrington SJ, Kaye CM et al. Observations on the clinical pharmacology and plasma concentrations of diacetolol, the major human metabolite of acebutolol. Br J Clin Pharmacol. 1981; 12:561-5. https://pubmed.ncbi.nlm.nih.gov/7295489 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1401897/

117. Flouvat B, Roux A, Delhotal B et al. The beta-blocking effect of diacetolol in humans and its relationship to plasma levels. Int J Clin Pharmacol Ther Toxicol. 1982; 20:358-61. https://pubmed.ncbi.nlm.nih.gov/6126441

118. Flouvat B, Roux A, Chau NP et al. Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol. Eur J Clin Pharmacol. 1981; 19:287-92. https://pubmed.ncbi.nlm.nih.gov/7286031

119. Kaye CM. New drugs: beta blockers and sympathomimetics. BMJ. 1983; 286:1439. https://pubmed.ncbi.nlm.nih.gov/6404493 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1547844/

120. Feely J, deVane PJ, Maclean D. Beta-blockers and sympathomimetics. BMJ. 1983; 286:1043-7. https://pubmed.ncbi.nlm.nih.gov/6131725 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1547508/

121. Kaye CM, Long AD. The influence of pH on the buccal absorption and plasma and renal elimination of acebutolol. Br J Clin Pharmacol. 1976; 3:196-7. https://pubmed.ncbi.nlm.nih.gov/9955 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1428818/

122. Roux A, Henry JF, Fouache Y et al. A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. Gerontology. 1983; 29:202-8. https://pubmed.ncbi.nlm.nih.gov/6852547

123. Munn S, Bailey RR, Begg E et al. Plasma and urine concentrations of acebutolol and its acetyl metabolite in patients with renal functional impairment. N Z Med J. 1980; 91:289-91. https://pubmed.ncbi.nlm.nih.gov/6930006

124. Kirch W, Kohler H, Berggren G et al. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite. Clin Nephrol. 1982; 18:88-94. https://pubmed.ncbi.nlm.nih.gov/7140021

125. Roux A, Aubert P, Guedon J et al. Pharmacokinetics of acebutolol in patients with all grades of renal failure. Eur J Clin Pharmacol. 1980; 17:339-48. https://pubmed.ncbi.nlm.nih.gov/7418713

126. Kaye CM, Dufton JF. Preliminary observations on the elimination of acebutolol in severe chronic renal failure. Br J Clin Pharmacol. 1976; 3:198-9. https://pubmed.ncbi.nlm.nih.gov/788740 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1428803/

127. Smith RS, Warren DJ, Renwick AG et al. Acebutolol pharmacokinetics in renal failure. Br J Clin Pharmacol. 1983; 16:253-8. https://pubmed.ncbi.nlm.nih.gov/6626416 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1427998/

128. Zaman R, Jack DB, Wilkins MR et al. Lack of effect of liver disease on the pharmacokinetics of acebutolol and diacetolol: a single dose study. Biopharm Drug Dispos. 1985; 6:131-7. https://pubmed.ncbi.nlm.nih.gov/4005393

129. Esler M, Zweifler A, Randall O et al. Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranolol. Clin Pharmacol Ther. 1978; 22:299-308.

130. Collste P, Haglund K, Frisk-Holmberg M et al. Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. Eur J Clin Pharmacol. 1976; 10:89-95. https://pubmed.ncbi.nlm.nih.gov/964292

131. Gibson TP, Matusik E, Nelson LD et al. Artificial kidneys and clearance calculations. Clin Pharmacol Ther. 1976; 20:720-6. https://pubmed.ncbi.nlm.nih.gov/991541

132. Pond S, Rosenberg J, Benowitz NL et al. Pharmacokinetics of haemoperfusion for drug overdose. Clin Pharmacokinet. 1979; 4:329-54. https://pubmed.ncbi.nlm.nih.gov/389527

133. Lee CSC, Marbury TC. Drug therapy in patients undergoing haemodialysis: clinical pharmacokinetic considerations. Clin Pharmacokinet. 1984; 9:42-66. https://pubmed.ncbi.nlm.nih.gov/6362952

134. Pond SM. Renal principles: diuresis, dialysis, and hemoperfusion. In: Goldfrank’s toxicologic emergencies. 3rd ed. Norwalk, CT: Appleton-Century-Crofts; 1986:102-15.

135. Jack DB, Quarterman CP, Zaman R et al. Variability of beta-blocker pharmacokinetics in young volunteers. Eur J Clin Pharmacol. 1982; 23:37-42. https://pubmed.ncbi.nlm.nih.gov/6127220

136. Tjandramaga TB. Altered pharmacokinetics of β-adrenoceptor blocking drugs in patients with renal insufficiency. Arch Int Pharmacodyn Ther. 1980; 247(Suppl):38-53.

137. Gradman AH, Winkle RA, Fitzgerald JW et al. Suppression of premature ventricular contractions by acebutolol. Circulation. 1977; 55:785-91. https://pubmed.ncbi.nlm.nih.gov/66105

138. DiBianco R, Singh SN, Shah PM et al. Comparison of the antianginal efficacy of acebutolol and propranolol. Circulation. 1982; 65:119-28.

139. Fournier A, Hardin JM, Alexandre JM et al. Anti-hypertensive effect of acebutolol: its relation to sympathetic nervous system responsiveness and to plasma renin and dopamine-β-hydroxylase activities. Clin Sci Mol Med. 1976; 51:477-80s.

140. Martin MA, Phillips CA, Smith AJ. Acebutolol in hypertension—a double-blind trial against placebo. Br J Clin Pharmacol. 1978; 6:351-6. https://pubmed.ncbi.nlm.nih.gov/359018 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429467/

141. Menard J, Bertagna X, N’Guyen PT et al. Rapid identification of patients with essential hypertension sensitive to acebutolol (a new cardioselective beta-blocker). Am J Med. 1976; 60:886-90. https://pubmed.ncbi.nlm.nih.gov/14503

142. Belleau LJ, Lebel M, Brossard JJ. Merits of adding a beta blocker (acebutolol) to a diuretic (hydrochlorothiazide) in the treatment of hypertension. J Clin Pharmacol. 1982; 22:20-7. https://pubmed.ncbi.nlm.nih.gov/7037871

143. Alhenc-Gelas F, Plouin PF, Ducrocq MB et al. Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker, acebutolol, and diuretics in essential hypertension. Am J Med. 1978; 64:1005-12. https://pubmed.ncbi.nlm.nih.gov/655186

144. Gorkin JU, Elijovich F, Dziedzic SW et al. Addition of acebutolol to diuretics in hypertension. Clin Pharmacol Ther. 1981; 30:739-44. https://pubmed.ncbi.nlm.nih.gov/6118215

145. Thibonnier M, Lardoux MD, Corvol P. Comparative trial of labetalol and acebutolol, alone or associated with dihydralazine, in treatment of essential hypertension. Br J Clin Pharmacol. 1980; 9:561-7. https://pubmed.ncbi.nlm.nih.gov/6992823 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1430010/

146. Begg E, Munn S, Bailey RR. Acebutolol in the treatment of patients with hypertension and renal functional impairment. N Z Med J. 1979; 89:293-5. https://pubmed.ncbi.nlm.nih.gov/286923

147. Heel RC, Brogden RN, Speight TM et al. Atenolol: a review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs. 1979; 17:425-60. https://pubmed.ncbi.nlm.nih.gov/38096

148. Merck Sharp & Dohme. Blocadren prescribing information. West Point, PA; 1985 Apr.

149. Gabriel R. Acebutolol in the management of hypertension in patients with renal disease. Br J Clin Pract. 1979; 33:259-62. https://pubmed.ncbi.nlm.nih.gov/486303

150. Wahl J, Singh BN, Thoden WR. Comparative hypotensive effects of acebutolol and hydrochlorothiazide in patients with mild to moderate essential hypertension: a double-blind multicenter evaluation. Am Heart J. 1986; 111:353-62. https://pubmed.ncbi.nlm.nih.gov/3511650

151. Hansson L, Berglund G, Andersson O et al. Controlled trial of acebutolol in hypertension. Eur J Clin Pharmacol. 1977; 12:89-92. https://pubmed.ncbi.nlm.nih.gov/336378

152. Wahl J, Turlapaty P, Singh BN et al. Comparison of acebutolol and propranolol in essential hypertension. Am Heart J. 1985; 109:313-21. https://pubmed.ncbi.nlm.nih.gov/3880995

153. Singh AN, Paul L, Brossard JJ. Double-blind cross-over study of two beta-blocking agents acebutolol and propranolol in essential hypertension. Curr Ther Res. 1980; 28:964-71.

154. Davidov M. Acebutolol in essential hypertension: results of two multicenter studies against placebo and propranolol. Am Heart J. 1985; 109(5 Part 2):1158-67. https://pubmed.ncbi.nlm.nih.gov/2859780

155. Manttari M, Eisalo A. A comparison of two cardioselective beta-blockers with different ancillary properties in the treatment of hypertension. Acta Med Scand. 1982; 668(Suppl):114-7.

156. Turner AS, Brocklehurst JC. Once-daily acebutolol and atenolol in essential hypertension: double-blind crossover comparison. Am Heart J. 1985; 109(5 Part 2):1178-83. https://pubmed.ncbi.nlm.nih.gov/3993534

157. Hua ASP, Kalowski S, Whitworth JA et al. Acebutolol in mild to moderate hypertension. Med J Aust. 1980; 1:226-8. https://pubmed.ncbi.nlm.nih.gov/6990216

158. Baker PG, Goulton J. A multicentre study of a once daily dosage of acebutolol in the treatment of hypertension in general practice. J Int Med Res. 1979; 7:201-14. https://pubmed.ncbi.nlm.nih.gov/456733

159. Nadeau J, Ogilvie RI, Ruedy J et al. Acebutolol and hydrochlorothiazide in essential hypertension. Clin Pharmacol Ther. 1980; 28:296-301. https://pubmed.ncbi.nlm.nih.gov/7408389

160. Franz IW. Differential antihypertensive effect of acebutolol and hydrochlorothiazide/amiloride hydrochloride combination on elevated exercise blood pressures in hypertensive patients. Am J Cardiol. 1980; 46:301-5. https://pubmed.ncbi.nlm.nih.gov/6105821

161. Leary WP, Asmal AC, Williams PC. Aldactone and acebutolol in treatment of hypertension. J Int Med Res. 1979; 7:29-32. https://pubmed.ncbi.nlm.nih.gov/369923

162. Khalil SI, El Zein O, Bella ME. A double-blind, crossover study of acebutolol and hydrochlorothiazide/amiloride diuretic in Sudanese patients with essential hypertension. Curr Med Res Opin. 1982; 8:39-43. https://pubmed.ncbi.nlm.nih.gov/7049584

163. Oli JM. Acebutolol in the management of hypertension in Nigerians. Curr Ther Res. 1981; 30:477-82.

164. MacGregor GA, Banks RA, Markandu ND et al. Lack of effect of beta-blocker on flat dose response to thiazide in hypertension: efficacy of low dose thiazide combined with beta-blocker. BMJ. 1983; 286:1535-8. https://pubmed.ncbi.nlm.nih.gov/6405876 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1548006/

165. Nievel JG, Havard CWH. Assessment of the efficacy and acceptability of an acebutolol/hydrochlorothiazide combination in the treatment of mild to moderate essential hypertension. Curr Med Res Opin. 1981; 7:526-35. https://pubmed.ncbi.nlm.nih.gov/7030637

166. Mitenko PA, McKenzie JK, Brossard JJ. Antihypertensive action of acebutolol (Sectral) when used concomitantly with hydrochlorothiazide. Br J Clin Pharmacol. 1982; 13:209-12. https://pubmed.ncbi.nlm.nih.gov/7059418 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1401992/

167. Ogilvie RI, Nadeau JH. Cardiovascular effects of acebutolol and hydrochlorothiazide in essential hypertension. Hypertension. 1982; 4:320-4. https://pubmed.ncbi.nlm.nih.gov/7040230

168. Down PF, Rao SK, Braverman AM et al. Treatment of hypertension in the elderly with a low dose combination of a beta-adrenoceptor blocker and a thiazide diuretic: comparison with methyldopa. Br J Clin Pract. 1983; 37:371-4,88. https://pubmed.ncbi.nlm.nih.gov/6367793

169. Fraser DM, Nimmo GR, Poloniecki JD. Acebutolol in the treatment of diabetic patients with hypertension. Curr Med Res Opin. 1986; 10:122-7. https://pubmed.ncbi.nlm.nih.gov/3519092

170. Boyles PW. Effects of age and race on clinical response to acebutolol in essential hypertension. Am Heart J. 1985; 109(5 Part 2):1184-92. https://pubmed.ncbi.nlm.nih.gov/2859783

171. Costa FV, Caldari R, Borghi C et al. Acebutolol, atenolol and nadolol: comparison of their antihypertensive efficacy at rest and during exercise. Curr Ther Res. 1984; 35:961-73.

173. Anon. Drugs for hypertension. Med Lett Drugs Ther. 1984; 26:107-12. https://pubmed.ncbi.nlm.nih.gov/6150424

174. Moser M. Initial treatment of adult patients with essential hypertension. Part I: why conventional stepped-care therapy of hypertension is still indicated. Pharmacotherapy. 1985; 5:189-95. https://pubmed.ncbi.nlm.nih.gov/2863806

175. Kaplan NM. Initial treatment of adult patients with essential hypertension. Part II: alternating monotherapy is the preferred treatment. Pharmacotherapy. 1985; 5:195-200. https://pubmed.ncbi.nlm.nih.gov/4034407

176. World Health Organization/International Society of Hypertension Fourth Mild Hypertension Conference. 1986 guidelines for the treatment of mild hypertension: memorandum from the WHO/ISH. Hypertension. 1986; 8:957-61.

178. Weiner N. Drugs that inhibit adrenergic nerves and block adrenergic receptors. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:181-214.

179. Rudd P, Blaschke TF. Antihypertensive agents and the drug therapy of hypertension. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:784-805.

180. Kaplan NM. Mild hypertension: when and how to treat. Arch Intern Med. 1983; 143:255-9. https://pubmed.ncbi.nlm.nih.gov/6130750

181. Kaplan NM. Non-drug treatment of hypertension. Ann Intern Med. 1985; 102:359-73. https://pubmed.ncbi.nlm.nih.gov/3882040

182. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Return of elevated blood pressure after withdrawal of antihypertensive drugs. Circulation. 1975; 51:1107-13. https://pubmed.ncbi.nlm.nih.gov/1093758

183. Kaplan NM. New choices for the initial drug therapy of hypertension. Am J Cardiol. 1983; 51:1786-8. https://pubmed.ncbi.nlm.nih.gov/6134465

184. Lewis JE. Comparison of acebutolol and hydrochlorothiazide in essential hypertension. Am Heart J. 1985; 109(5 Part 2):1168-74. https://pubmed.ncbi.nlm.nih.gov/2859781

185. de Soyza N, Shapiro W, Chandraratna PAN et al. Acebutolol therapy for ventricular arrhythmia: a randomized, placebo-controlled, double-blind multicenter study. Circulation. 1982; 65:1129-33. https://pubmed.ncbi.nlm.nih.gov/7042111

186. Lui HK, Lee G, Dhurandhar R et al. Reduction of ventricular ectopic beats with oral acebutolol: a double-blind, randomized crossover study. Am Heart J. 1983; 105:722-6. https://pubmed.ncbi.nlm.nih.gov/6846115

187. Burckhardt D, Raeder EA. The effect of acebutolol on cardiac arrhythmias in patients with chronic coronary artery disease. Am Heart J. 1980; 99:443-5. https://pubmed.ncbi.nlm.nih.gov/6102434

188. Peretz DI, McMurtry TJ. Evaluation of the clinical effectiveness of acebutolol, a cardio-specific beta-adrenergic blocking agent, in the suppression of premature ventricular contractions. Curr Ther Res. 1979; 26:557-61.

189. Singh SN, DiBianco R, Davidov ME et al. Comparison of acebutolol and propranolol for treatment of chronic ventricular arrhythimia: a placebo-controlled, double-blind, randomized crossover study. Circulation. 1982; 65:1356-64. https://pubmed.ncbi.nlm.nih.gov/6176357

190. Shapiro W, Park J, Koch GG. Variability of spontaneous and exercise-induced ventricular arrhythmias in the absence and presence of treatment with acebutolol or quinidine. Am J Cardiol. 1982; 49:445-54. https://pubmed.ncbi.nlm.nih.gov/6174041

191. Labram C. Control of cardiac arrhythmias: the use of acebutolol. Clin Trials J. 1974; 3:115-20.

192. Williams DO, Tatelbaum R, Most AS. Effective treatment of supraventricular arrhythmias with acebutolol. Am J Cardiol. 1979; 44:521-5. https://pubmed.ncbi.nlm.nih.gov/382821

193. Ahumada GG, Karlsberg RP, Jaffe AS et al. Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction. Br Heart J. 1979; 41:654-9. https://pubmed.ncbi.nlm.nih.gov/465240 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC482087/

194. de Soyza N, Kane JJ, Murphy ML et al. The long-term suppression of ventricular arrhythmia by oral acebutolol in patients with coronary artery disease. Am Heart J. 1980; 100:631-8. https://pubmed.ncbi.nlm.nih.gov/6778183

195. de Soyza N. Acebutolol for premature ventricular contractions: short- and long-term effects. Am Heart J. 1985; 109(5 Part 2):1205-9. https://pubmed.ncbi.nlm.nih.gov/3993536

196. Khambatta RB. Clinical tachydysrhythmias: the effect of acebutolol (Sectral) on tachydysrhythmias in general and after myocardial infarction. Clin Trials J. 1971; 11:109-14.

197. Aronow WS, Turbow M, Lurie M et al. Treatment of premature ventricular complexes with acebutolol. Am J Cardiol. 1979; 43:106-8. https://pubmed.ncbi.nlm.nih.gov/758758

198. Chandraratna PAN. Comparison of acebutolol with propranolol, quinidine, and placebo: results of three multicenter arrhythmia trials. Am Heart J. 1985; 109(5 Part 2):1198-204. https://pubmed.ncbi.nlm.nih.gov/3993535

199. Glasser SP, Clark PI, Laddu AR. Comparison of the antiarrhythmic effects of acebutolol and propranolol in the treatment of ventricular arrhythmias. Am J Cardiol. 1983; 52:992-5. https://pubmed.ncbi.nlm.nih.gov/6195911

200. Aronow WS, Van Camp S, Turbow M et al. Acebutolol in supraventricular arrhythmias. Clin Pharmacol Ther. 1979; 25:149-53. https://pubmed.ncbi.nlm.nih.gov/365429

201. Aronow WS, Wong R, Plasencia G et al. Effect of acebutolol and propranolol on premature ventricular complexes. Clin Pharmacol Ther. 1980; 28:28-31. https://pubmed.ncbi.nlm.nih.gov/6993085

202. Letac B. Treatment of cardiac arrhythmias: use of intravenous acebutolol. Clin Trials J. 1974; 11:105-8.

203. Gotsman MS, Lewis BS, Mitha AS. Acebutolol (Sectral) in the treatment of cardiac arrhythmias. Clin Trials J. 1974; 11:121-6.

204. Platia EV, Berdoff R, Stone G et al. Comparison of acebutolol and propranolol therapy for ventricular arrhythmias. J Clin Pharmacol. 1985; 25:130-7. https://pubmed.ncbi.nlm.nih.gov/2580866

205. DiBianco R, Singh S, Singh JB et al. Effects of acebutolol on chronic stable angina pectoris: a placebo-controlled, double-blind, randomized crossover study. Circulation. 1980; 62:1179-87. https://pubmed.ncbi.nlm.nih.gov/6777070

206. Lee G, DeMaria AN, Favrot L et al. Efficacy of acebutolol in chronic stable angina using single-blind and randomized double-blind protocol. J Clin Pharmacol. 1982; 22:371-8. https://pubmed.ncbi.nlm.nih.gov/6813360

207. Tremblay G, Biron P, Proulx A. Acebutolol: efficacy of a single daily dose in angina pectoris. Curr Ther Res. 1979; 25:637-40.

208. Tremblay G, Biron P, Caille G et al. Double-blind crossover trial of single- versus twice-daily doses of acebutolol in angina. Curr Ther Res. 1981; 29:644-50.

209. Rod JL, Admon D, Kimchi A et al. Evaluation of the beta-blocking drug acebutolol in angina pectoris. Am Heart J. 1979; 98:604-12. https://pubmed.ncbi.nlm.nih.gov/495406

210. Macdonald IL, Culbert PS, Robertson JW et al. A comparison study of acebutolol, a cardiospecific β-adrenergic blocker, and propranolol in the treatment of angina pectoris. Curr Ther Res. 1978; 24:470-8.

211. DiBianco R, Singh SN, Shah PM et al. Comparison of the antianginal efficacy of acebutolol and propranolol: a multicenter, randomized, double-blind placebo-controlled study. Circulation. 1982; 65:1119-28. https://pubmed.ncbi.nlm.nih.gov/6804109

212. Ross MB, Levine P. A double-blind cross-over evaluation of acebutolol and propranolol in patients with angina pectoris. Curr Ther Res. 1981; 29:202-7.

213. Biron P, Tremblay G, Proulx A. Double-blind crossover comparison of acebutolol and propranolol in angina. Clin Pharmacol Ther. 1978; 23:109.

214. Rotem CE, Carruthers J, Byrne A. Long-term management of angina pectoris with acebutolol. Curr Ther Res. 1979; 26:562-7.

215. Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981; 305:500-6. https://pubmed.ncbi.nlm.nih.gov/6114433

216. Opie LH. Drugs and the heart. Lancet. 1980; 1:693-8. https://pubmed.ncbi.nlm.nih.gov/6103100

217. Leonard RG, Talbert RL. Calcium-channel blocking agents. Clin Pharm. 1982; 1:17-33. https://pubmed.ncbi.nlm.nih.gov/6764159

218. K.dtdberg RP. Calcium channel blockers for cardiovascular disorders. Arch Intern Med. 1982; 142:452-5.

219. Zelis R. Calcium-blocker therapy for unstable angina pectoris. N Engl J Med. 1982; 306:926-8. https://pubmed.ncbi.nlm.nih.gov/6121290

220. Biron P, Tremblay G. Differential antianginal responsiveness to acebutolol. Eur J Clin Pharmacol. 1975; 8:15-9. https://pubmed.ncbi.nlm.nih.gov/786672

221. Kimchi A, Gotsman MS, Lewis BS. Acebutolol in angina pectoris: objective assessment using graded treadmill testing. Isr J Med Sci. 1978; 14:941-7. https://pubmed.ncbi.nlm.nih.gov/363642

222. Gotsman MS, Lewis BS. The treatment of angina pectoris: an objective assessment of oral acebutolol (Sectral). Clin Trials J. 1974; 11(Suppl 3):80-5.

223. Pfisterer M, Muller-Brand J, Burkart F. Combined acebutolol/nifedipine therapy in patients with chronic coronary artery disease: additional improvement of ischemia-induced left ventricular dysfunction. Am J Cardiol. 1982; 49:1259-66. https://pubmed.ncbi.nlm.nih.gov/7064850

224. Steele P, Gold F. Favorable effects of acebutolol on exercise performance and angina in men with coronary artery disease. Chest. 1982; 82:40-3. https://pubmed.ncbi.nlm.nih.gov/7044708

225. De Ponti C, De Biase AM, Cataldo G et al. Effects of nifedipine, acebutolol, and their association on exercise tolerance in patients with effort angina. Cardiology. 1981; 68(Suppl 2):195-9. https://pubmed.ncbi.nlm.nih.gov/7032697

226. Geigy Pharmaceuticals. Lopressor prescribing information. In: Huff BB, ed. Physicians’ desk reference. 41st ed. Oradell, NJ: Medical Economics Company Inc; 1987:956-60.

227. Booth RJ, Wilson JD, Bullock JY. β-Adrenergic-receptor blockers and antinuclear antibodies in hypertension. Clin Pharmacol Ther. 1982; 31:555-63. https://pubmed.ncbi.nlm.nih.gov/6122525

228. Akoun GM, Herman DP, Mayaud CM et al. Acebutolol-induced hypersensitivity pneumonitis. BMJ. 1983; 286:266-7. https://pubmed.ncbi.nlm.nih.gov/6402066 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1546532/

229. Akoun GM, Mayaud CM, Milleron BJ et al. Drug-related pneumonitis and drug-induced hypersensitivity pneumonitis. Lancet. 1984; 1:1362. https://pubmed.ncbi.nlm.nih.gov/6145066

230. Cody RJ Jr, Calabrese LH, Clough JD et al. Development of antinuclear antibodies during acebutolol therapy. Clin Pharmacol Ther. 1979; 25:800-5. https://pubmed.ncbi.nlm.nih.gov/87291

231. Tirlapur VG, Evans PJ, Jones MK. Shock syndrome after acebutolol. Br J Clin Pract. 1986; 40:33-4. https://pubmed.ncbi.nlm.nih.gov/3707825

232. Piette JC, Bourgeois P, Herson S et al. Acebutolol-induced lupus (AIL). Arthritis Rheum. 1985; 28(Suppl 4S):S52.

233. Record NB Jr. Acebutolol-induced pleuropulmonary lupus syndrome. Ann Intern Med. 1981; 95:326-7. https://pubmed.ncbi.nlm.nih.gov/6973944

234. Wood GM, Bolton RP, Muers MF et al. Pleurisy and pulmonary granulomas after treatment with acebutolol. BMJ. 1982; 285:936. https://pubmed.ncbi.nlm.nih.gov/6811073 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1499959/

235. Leggett RJE. Pleurisy and pulmonary granulomas after treatment with acebutolol. BMJ. 1982; 285:1425.

236. Lyall MG, Bainbridge JG, Khambatta RB. Ophthalmological monitoring of patients receiving long-term acebutolol. Br J Clin Pharmacol. 1983; 16:574-6. https://pubmed.ncbi.nlm.nih.gov/6639845 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1428070/

237. Welsh N, Leary WP, Van Der Byl K. Acebutolol: prolonged administration without ophthalmological complications. Curr Ther Res. 1983; 33:611-5.

238. Martin DE, Kammerer WS. The hypertensive surgical patient: controversies in management. Surg Clin North Am. 1983; 63:1017-33. https://pubmed.ncbi.nlm.nih.gov/6138862

239. Dumez Y, Chobroutsky C, Hornych H et al. Neonatal effects of maternal administration of acebutolol. BMJ. 1981; 283:1077-9. https://pubmed.ncbi.nlm.nih.gov/6794766 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1507531/

240. Williams ER, Morrissey JR. A comparison of acebutolol with methyldopa in hypertensive pregnancy. Pharmatherapeutica. 1983; 3:487-91. https://pubmed.ncbi.nlm.nih.gov/6669592

241. Dubois D, Petitcolas J, Temperville B et al. Treatment of hypertension in pregnancy with β-adrenoceptor antagonists. Br J Clin Pharmacol. 1982; 13(Suppl):375-8S. https://pubmed.ncbi.nlm.nih.gov/7059437 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1402120/

242. Lewis M, Kallenbach J, Germond C et al. Survival following massive overdose of adrenergic blocking agents (acebutolol and labetalol). Eur Heart J. 1983; 4:328-32. https://pubmed.ncbi.nlm.nih.gov/6617679

243. Sangster B, de Wildt D, van Dijk A. A case of acebutolol intoxication. J Toxicol Clin Toxicol. 1983; 20:69-77. https://pubmed.ncbi.nlm.nih.gov/6887301

244. Zaman R, Kendall MJ. The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide. Br J Clin Pharmacol. 1982; 13:507-12. https://pubmed.ncbi.nlm.nih.gov/6802160 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1402050/

245. Ashton WL. An open, multicentre study of acebutolol, given as a single daily dose, in the management of hypertension. Curr Med Res Opin. 1977; 5:279-83. https://pubmed.ncbi.nlm.nih.gov/162667

246. Ashton WL. Acebutolol (400 mg) given as a single daily dose to hypertensive patients previously stabilized on 400 mg acebutolol daily in divided doses: an open multicentre study. Curr Med Res Opin. 1978; 5:347-53.

247. Watson RDS, Stallard TJ, Littler WA. Comparison of once and twice daily administration of acebutolol in hypertension. Br J Clin Pharmacol. 1980; 9:209-12. https://pubmed.ncbi.nlm.nih.gov/6766731 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429867/

248. Frick MH, Kala R. Antiarrhythmic significance of dosing intervals in beta receptor blocking therapy of hypertension with acebutolol. Am J Cardiol. 1981; 48:911-6. https://pubmed.ncbi.nlm.nih.gov/6118059

249. Klug E, Schneider V. Todliche Vergiftung mit Acebutolol (Prent). (German; with English abstract.) Z Rechtsmed. 1979; 83:325-30.

250. Beyer H, Blank P, Kelch L et al. Letale Vergiftung mit Acebutolol. (German; with English abstract.) Intensivmed Prax. 1981; 18:83-5.

251. Cruickshank JM. The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J. 1980; 100:160-78. https://pubmed.ncbi.nlm.nih.gov/6105819

252. Woods PB, Robinson ML. An investigation of the comparative liposolubilities of β-adrenoceptor blocking agents. J Pharm Pharmacol. 1981; 33:172-3. https://pubmed.ncbi.nlm.nih.gov/6116760

253. The United States pharmacopeia, 24th rev, and The national formulary, 19th ed. Rockville, MD: The United States Pharmacopeial Convention, Inc; 2000:15.

254. Bigger JT Jr, Hoffman BF. Antiarrhythmic drugs. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:748-83.

255. Chatterji AN. A randomized crossover comparison of acebutolol and methyldopa in the treatment of mild to moderate essential hypertension. Curr Med Res Opin. 1978; 5:675-81. https://pubmed.ncbi.nlm.nih.gov/367712

256. Anon. Drugs for cardiac arrhythmias. Med Lett Drugs Ther. 1986; 28:111-6. https://pubmed.ncbi.nlm.nih.gov/2878351

257. Gosselin RE, Smith RP, Hodge HC. Clinical toxicology of commercial products. 5th ed. Baltimore: Williams & Wilkins; 1984:I-8.

258. Frishman W, Jacob H, Eisenberg E et al. Clinical pharmacology of the new β-adrenergic blocking drugs. Part 8. Self-poisoning with beta-adrenoceptor blocking agents: recognition and management. Am Heart J. 1979; 98:798-811. https://pubmed.ncbi.nlm.nih.gov/40429

259. Weinstein RS. Recognition and management of poisoning with beta-adrenergic blocking agents. Ann Emerg Med. 1984; 13:1123-31. https://pubmed.ncbi.nlm.nih.gov/6150667

260. Anon. Beta-blocker poisoning. Lancet. 1980; 1:803-4.

261. Machin PJ, Hurst DN, Bradshaw RN et al. β-Selective adrenoceptor antagonists. Part 2: 4-ether-linked phenoxypropanolamines. J Med Chem. 1983; 26:1570-6. https://pubmed.ncbi.nlm.nih.gov/6138435

262. Broadhurst AD. Comparison of effect on psychomotor performance of single doses of propranolol and acebutolol. Curr Med Res Opin. 1980; 7:33-8. https://pubmed.ncbi.nlm.nih.gov/7428410

263. Kayed K, Godtlibsen OB. Central effects of the β-adrenergic blocking agent acebutolol: a quantitative EEG study using normalised slope descriptors. Eur J Clin Pharmacol. 1977; 12:327-31. https://pubmed.ncbi.nlm.nih.gov/598404

264. Kayed K, Godtlibsen OB. Effects of the β-adrenoceptor antagonists acebutolol and metoprolol on sleep pattern in normal subjects. Eur J Clin Pharmacol. 1977; 12:323-6. https://pubmed.ncbi.nlm.nih.gov/598403

265. Lewis MJ, Jones DM, Dart AM et al. The psychological side effects of acebutolol and atenolol. Br J Clin Pharmacol. 1984; 17:364-6. https://pubmed.ncbi.nlm.nih.gov/6712870 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1463380/

266. Lewis BS, Mitha AS, Gotsman MS. Acebutolol in cardiac arrhythmias. S Afr Med J. 1974; 4:821-4.

267. Booth RJ, Bullock JY, Wilson JD. Antinuclear antibodies in patients on acebutolol. Br J Clin Pharmacol. 1980; 9:515-7. https://pubmed.ncbi.nlm.nih.gov/6104977 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1429946/

268. Wilson FS (Wyeth Laboratories Inc, Philadelphia, PA): Personal communication; 1987.

269. Anon. Choice of a beta-blocker. Med Lett Drugs Ther. 1986; 28:20-2. https://pubmed.ncbi.nlm.nih.gov/2869400

270. Wallin JD, Shah SV. β-Adrenergic blocking agents in the treatment of hypertension: choices based on pharmacological properties and patient characteristics. Arch Intern Med. 1987; 147:654-9. https://pubmed.ncbi.nlm.nih.gov/2881524

271. McDevitt DG. β-Adrenoceptor blocking drugs and partial agonist activity: is it clinically relevant? Drugs. 1983; 25:331-8.

272. McDevitt DG. Clinical significance of cardioselectivity: state-of-the-art. Drugs. 1983; 25(Suppl 2):219-26.

273. Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981; 305:500-6. https://pubmed.ncbi.nlm.nih.gov/6114433

274. Thadani U, Davidson C, Chir B et al. Comparison of the immediate effects of five β-adrenoceptor-blocking drugs with different ancillary properties in angina pectoris. N Engl J Med. 1979; 300:750-5. https://pubmed.ncbi.nlm.nih.gov/581782

275. Lewis RV, McDevitt DG. Adverse reactions and interactions with β-adrenoceptor blocking drugs. Med Toxicol. 1986; 1:343-61. https://pubmed.ncbi.nlm.nih.gov/2878346

276. Bradberry JC. Discontinuing β blockers. Clin Pharm. 1984; 3:457,460.

277. Reviewers’ comments (personal observations); 1987.

278. Frishman WH. Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitution. Am Heart J. 1987; 113:1190-8. https://pubmed.ncbi.nlm.nih.gov/2883867

279. Abengowe CU, Rehan N. Acebutolol in the treatment of hypertension in African patients. Curr Ther Res. 1987; 41:737-45.

280. 1988 Joint National Committee. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988; 148:1023-38. https://pubmed.ncbi.nlm.nih.gov/3365073

281. Tanner LA, Bosco LA, Zimmerman HJ. Hepatic toxicity after acebutolol therapy. Am Intern Med. 1989; 111:533-4.

282. Webster J. Interactions of NSAIDs with diuretics and β-blockers: mechanisms and clinical implications. Drugs. 1985; 30:32-41. https://pubmed.ncbi.nlm.nih.gov/2863124

283. Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med. 1987; 107:628-35. https://pubmed.ncbi.nlm.nih.gov/2889416

284. Watkins J, Abbott EC, Hensby CN et al. Attenuation of hypotensive effects of propranolol and thiazide diuretics by indomethacin. Br Med J. 1980; 281:702-5. https://pubmed.ncbi.nlm.nih.gov/7427409 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1713997/

285. Mills EH, Whitworth JA, Andrews J et al. Non-steroidal anti-inflammatory drugs and blood pressure. Aust N Z J Med. 1982; 12:478-82. https://pubmed.ncbi.nlm.nih.gov/6758745

286. Durao V, Prata MM, Goncalves LMP. Modification of antihypertensive effect of β-adrenoreceptor-blocking agents by inhibition of endogenous prostaglandin synthesis. Lancet. 1977; 2:1005-7. https://pubmed.ncbi.nlm.nih.gov/72901

287. Salvetti A, Arzilli F, Pedrinelli R et al. Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients. Eur J Clin Pharmacol. 1982; 22:197-201. https://pubmed.ncbi.nlm.nih.gov/7049707

288. Beta blockers/NSAIDs. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1989: 154.

289. Boissel JP, Lezorovicz A, Picolet H et al. Efficacy of acebutolol after acute myocardial infarction (the APSI Trial). Am J Cardiol. 1990; 66:24-31C.

290. Boissel JP, Leizorovicz A, Picolet H et al. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol. 1990; 66:251-60. https://pubmed.ncbi.nlm.nih.gov/2195860

291. De Backer G. Multicentre study of the efficacy and tolerance of acebutolol versus atenolol in the long term treatment of mild arterial hypertension. Drugs. 1988; 36(Suppl 2):51-6. https://pubmed.ncbi.nlm.nih.gov/3063506

292. Clucas A, Miller N. Effects of acebutolol on the serum lipid profile. Drugs. 1988; 36(Suppl 2):41-50. https://pubmed.ncbi.nlm.nih.gov/3063505

293. Reviewers’ comments (personal observations).

294. American College of Cardiology and American Heart Association. ACC/AHA guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). Circulation. 1990; 82:664-707. https://pubmed.ncbi.nlm.nih.gov/2197021

295. Goldman L, Sia STB, Cook EF et al. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med. 1988; 319:152-7. https://pubmed.ncbi.nlm.nih.gov/2898733

296. Yusuf S, Peto R, Lewis J et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985; 27:335-71. https://pubmed.ncbi.nlm.nih.gov/2858114

297. Pedersen TR for the Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian multicenter study on timolol after acute myocardial infarction. N Engl J Med. 1985; 313:1055-8. https://pubmed.ncbi.nlm.nih.gov/2864634

298. Frishman WH, Furberg CD, Friedewald WT. β-Adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med. 1984; 310:830-7. https://pubmed.ncbi.nlm.nih.gov/6142420

299. Furberg CD. Secondary prophylaxis after acute myocardial infarction. Am J Cardiol. 1987; 60:28-32A. https://pubmed.ncbi.nlm.nih.gov/3604941

300. Australian and Swedish Pindolol Study Group. The effect of pindolol on the two years mortality after complicated myocardial infarction. Eur Heart J. 1983; 4:367-75. https://pubmed.ncbi.nlm.nih.gov/6617682

301. Schroder R. Oxprenolol in myocardial infarction survivors: brief review of the European infarction study results in light of other beta-blocker postinfarction trials. Z Kardiol. 1985; 74(Suppl 6):165-72. https://pubmed.ncbi.nlm.nih.gov/2869616

302. European Infarction Study Group. European infarction study (E.I.S.): a secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. Eur Heart J. 1984; 5:189-202. https://pubmed.ncbi.nlm.nih.gov/6373264

303. Taylor SH, Silke B, Ebbutt A et al. A long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med. 1982; 307:1293-1301. https://pubmed.ncbi.nlm.nih.gov/6752712

305. Wyeth-Ayerst Laboratories, Radnor, PA: Personal communication.

307. Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee fifth report. Arch Intern Med. 1993; 153:149-52. https://pubmed.ncbi.nlm.nih.gov/8422205

308. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: an overview of randomized drug trials in their epidemiological context. Lancet. 1990; 335:827-38. https://pubmed.ncbi.nlm.nih.gov/1969567

309. Alderman MH. Which antihypertensive drugs first—and why! JAMA. 1992; 267:2786-7. Editorial.

310. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335:765-74. https://pubmed.ncbi.nlm.nih.gov/1969518

311. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265:3255-64. https://pubmed.ncbi.nlm.nih.gov/2046107

312. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-hypertension). Lancet. 1991; 338:1281-5. https://pubmed.ncbi.nlm.nih.gov/1682683

313. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992; 304:405-12. https://pubmed.ncbi.nlm.nih.gov/1445513 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1995577/

314. National Heart, Lung, and Blood Institute. NHLBI panel reviews safety of calcium channel blockers. Rockville, MD; 1995 Aug 31. Press release.

315. National Heart, Lung, and Blood Institute. New analysis regarding the safety of calcium-channel blockers: a statement for health professionals from the National Heart, Lung, and Blood Institute. Rockville, MD; 1995 Sep 1.

316. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995; 274:620-5. https://pubmed.ncbi.nlm.nih.gov/7637142

317. Yusuf S. Calcium antagonists in coronary artery disease and hypertension: time for reevaluation? Circulation. 1995; 92:1079-82. Editorial.

318. Roche. Posicor (mibefradil hydrochloride) tablets prescribing information. Nutley, NJ; 1997 Dec.

319. Ellison RH. Dear doctor letter regarding appropriate use of Posicor. Nutley, NJ: Roche Laboratories; 1997 Dec.

320. Sidmak Laboratories. Verapamil hydrochloride tablets prescribing information. East Hanover, NJ; 1996 Apr.

321. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health; 1997 Nov. (NIH publication No. 98-4080.)

322. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80. https://pubmed.ncbi.nlm.nih.gov/8622249

323. Psaty BM, Smith NL, Siscovich DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997; 277:739-45. https://pubmed.ncbi.nlm.nih.gov/9042847

324. Whelton PK, Appel LJ, Espeland MA et al. for the TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998; 279:839-46. https://pubmed.ncbi.nlm.nih.gov/9515998

326. Genuth P. United Kingdom prospective diabetes study results are in. J Fam Pract. 1998; 47:(Suppl 5):S27.

328. Watkins PJ. UKPDS: a message of hope and a need for change. Diabet Med. 1998; 15:895-6. https://pubmed.ncbi.nlm.nih.gov/9827842

329. Bretzel RG, Voit K, Schatz H et al. The United Kingdom Prospective Diabetes Study (UKPDS): implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 1998; 106:369-72. https://pubmed.ncbi.nlm.nih.gov/9831300

330. Tatti P, Pahor M, Byington RP et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998; 21:597-603. https://pubmed.ncbi.nlm.nih.gov/9571349

331. American Diabetes Association. The United Kingdom Prospective Diabetes Study (UKPDS) for type 2 diabetes: what you need to know about the results of a long-term study. Washington, DC; 1998 Sep 15 from American Diabetes Association web site. http://www.diabetes.org

332. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317:713-20. https://pubmed.ncbi.nlm.nih.gov/9732338 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC28660/

333. Davis TME. United Kingdom Prospective Diabetes Study: the end of the beginning? Med J Aust. 1998; 169:511-2.

335. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: approaches to the prevention of heart failure. Am J Cardiol. 1999; 83:9A-38A.

336. Lim PO, MacDonald TM. Antianginal and β-adrenergic blocking drugs. In: Dukes MNG, ed. Meyler’s side effects of drugs. 13th ed. New York: Elsevier/North Holland Inc; 1996:488-535.

337. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000; 342:905-12. https://pubmed.ncbi.nlm.nih.gov/10738048

338. Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000; 342:969-70. https://pubmed.ncbi.nlm.nih.gov/10738057

339. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. https://pubmed.ncbi.nlm.nih.gov/10818056

340. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. https://pubmed.ncbi.nlm.nih.gov/10818055

341. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. https://pubmed.ncbi.nlm.nih.gov/10977801

342. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351:1755-62. https://pubmed.ncbi.nlm.nih.gov/9635947

345. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol. 2001; 38:1266i-lxx.

347. Ryan TJ, Antman EM, Brooks NH et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Managment of Acute Myocardial Infarction). From ACC web site. http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards.aspx

348. ACC/AHA guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Chronic Stable Angina). 2002. From ACC web site. Accessed 2003 Feb 13. http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards.aspx

349. Williams CL, Hayman LL, Daniels SR et al. Cardiovascular health in childhood: a statement for health professional from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2002; 106:143-60. https://pubmed.ncbi.nlm.nih.gov/12093785

350. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). 2002. From ACC web site. Accessed Sep. 10, 2002. http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards.aspx

352. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-60. https://pubmed.ncbi.nlm.nih.gov/12479770

353. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. https://pubmed.ncbi.nlm.nih.gov/12479763

355. Douglas JG, Bakris GL, Epstein M et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163:525-41.

357. The Guidelines Subcommitee of the WHO/ISH Mild Hypertension Liaison Committee. 1999 guidelines for the management of hypertension. J Hypertension. 1999; 17:392-403.

359. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-607. https://pubmed.ncbi.nlm.nih.gov/15811979

360. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005; 293:1663-6. https://pubmed.ncbi.nlm.nih.gov/15811986

361. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.

500. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Bethesda, MD: National Institutes of Health; 2004 Aug. (NIH publication No. 04-5230.)

501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-20. https://pubmed.ncbi.nlm.nih.gov/24352797

502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357. https://pubmed.ncbi.nlm.nih.gov/23817082

503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014; 63:878-85. https://pubmed.ncbi.nlm.nih.gov/24243703

504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014; 16:14-26. https://pubmed.ncbi.nlm.nih.gov/24341872

505. Wright JT, Fine LJ, Lackland DT et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014; 160:499-503. https://pubmed.ncbi.nlm.nih.gov/24424788

506. Mitka M. Groups spar over new hypertension guidelines. JAMA. 2014; 311:663-4. https://pubmed.ncbi.nlm.nih.gov/24549531

507. Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes?. JAMA. 2014; 311:474-6. https://pubmed.ncbi.nlm.nih.gov/24352710

508. Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA. 2014; 311:477-8. https://pubmed.ncbi.nlm.nih.gov/24352759

515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. Cleve Clin J Med. 2014; 81:178-88. https://pubmed.ncbi.nlm.nih.gov/24591473

523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471.

524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327.

526. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014; :. https://pubmed.ncbi.nlm.nih.gov/24788967

527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362-425. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695607/

530. Myers MG, Tobe SW. A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines. J Clin Hypertens (Greenwich). 2014; 16:246-8. https://pubmed.ncbi.nlm.nih.gov/24641124

536. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012: 2: 337-414.

800. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016; :.

1200. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71:el13-e115. https://pubmed.ncbi.nlm.nih.gov/29133356

1201. Bakris G, Sorrentino M. Redefining hypertension - assessing the new blood-pressure guidelines. N Engl J Med. 2018; 378:497-499. https://pubmed.ncbi.nlm.nih.gov/29341841

1202. Carey RM, Whelton PK, 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018; 168:351-358. https://pubmed.ncbi.nlm.nih.gov/29357392

1207. Burnier M, Oparil S, Narkiewicz K et al. New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. Blood Press. 2018; 27:62-65. https://pubmed.ncbi.nlm.nih.gov/29447001

1209. Qaseem A, Wilt TJ, Rich R et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017; 166:430-437. https://pubmed.ncbi.nlm.nih.gov/28135725

1210. SPRINT Research Group, Wright JT, Williamson JD et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103-16. https://pubmed.ncbi.nlm.nih.gov/26551272

1216. Taler SJ. Initial treatment of hypertension. N Engl J Med. 2018; 378:636-644. https://pubmed.ncbi.nlm.nih.gov/29443671

1220. Cifu AS, Davis AM. Prevention, detection, evaluation, and management of high blood pressure in adults. JAMA. 2017; 318:2132-2134. https://pubmed.ncbi.nlm.nih.gov/29159416

1222. Bell KJL, Doust J, Glasziou P. Incremental benefits and harms of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline. JAMA Intern Med. 2018; 178:755-7. https://pubmed.ncbi.nlm.nih.gov/29710197

1223. LeFevre M. ACC/AHA hypertension guideline: what is new? what do we do?. Am Fam Physician. 2018; 97(6):372-3. https://pubmed.ncbi.nlm.nih.gov/29671534

1224. Brett AS. New hypertension guideline is released. From NEJM Journal Watch website. Accessed 2018 Jun 18. https://www.jwatch.org/na45778/2017/12/28/nejm-journal-watch-general-medicine-year-review-2017

1229. Ioannidis JPA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. JAMA. 2018; 319(2):115-6. https://pubmed.ncbi.nlm.nih.gov/29242891

1235. Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens. 2017; 11(1):54-65. https://pubmed.ncbi.nlm.nih.gov/28057444

More about acebutolol

Patient resources

Professional resources

Acebutolol prescribing information

Related treatment guides

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

WADA Class Anti-Doping Classification

User Reviews & Ratings

6 Reviews

Images

Pill AMNEAL 669 is Acebutolol Hydrochloride 200 mg — Acebutolol Hydrochloride 200 mg (AMNEAL 669)